

## WJG 20<sup>th</sup> Anniversary Special Issues (6): *Helicobacter pylori*

# An association between *Helicobacter pylori* and upper respiratory tract disease: Fact or fiction?

Shin Kariya, Mitsuhiro Okano, Kazunori Nishizaki

Shin Kariya, Mitsuhiro Okano, Kazunori Nishizaki, Department of Otolaryngology-Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan

**Author contributions:** Kariya S and Okano M collected the underlying material; Kariya S wrote the initial draft of the manuscript; all authors designed the outline of the manuscript, finalized and revised the contents, and read and approved the final version of the manuscript.

**Supported by** JSPS KAKENHI (Grants-in-Aid for Scientific Research), No. 23791900 and No. 25462642

**Correspondence to:** Shin Kariya, MD, PhD, Department of Otolaryngology-Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan. [skariya@cc.okayama-u.ac.jp](mailto:skariya@cc.okayama-u.ac.jp)

Telephone: 81-86-2357307 Fax: 81-86-2357308

Received: September 16, 2013 Revised: November 13, 2013

Accepted: January 6, 2014

Published online: February 14, 2014

## Abstract

*Helicobacter pylori* (*H. pylori*) is a major cause of chronic gastritis and gastric ulcers and considerable evidence supports the notion that infection with this bacterium is also associated with gastric malignancy in addition to various other conditions including pulmonary, vascular and autoimmune disorders. Gastric juice infected with *H. pylori* might play an important role in upper respiratory tract infection. Although direct and/or indirect mechanisms might be involved in the association between *H. pylori* and upper respiratory tract diseases, the etiological role of *H. pylori* in upper respiratory tract disorders has not yet been fully elucidated. Although various studies over the past two decades have suggested a relationship between *H. pylori* and upper respiratory tract diseases, the findings are inconsistent. The present overview describes the outcomes of recent investigations into the impact of *H. pylori* on upper respiratory

tract and adjacent lesions.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Paranasal sinus; Ear; Adenoid; Oral cavity; Pharynx; Larynx; Upper respiratory tract; Cancer

**Core tip:** This review evaluates the role of *Helicobacter pylori* (*H. pylori*) in the upper respiratory system. Many studies have reported the presence of *H. pylori* in the upper respiratory tract, but their findings have varied. A definitive relationship between *H. pylori* and upper respiratory tract disorders has not been established, and further controlled studies are required.

Kariya S, Okano M, Nishizaki K. An association between *Helicobacter pylori* and upper respiratory tract disease: Fact or fiction? *World J Gastroenterol* 2014; 20(6): 1470-1484 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v20/i6/1470.htm> DOI: <http://dx.doi.org/10.3748/wjg.v20.i6.1470>

## INTRODUCTION

The Gram-negative bacterium *Helicobacter pylori* (*H. pylori*) resides in the human stomach, which was formerly considered a sterile environment due to its low pH<sup>[1]</sup>. Permanent *H. pylori* infection is often acquired early in life<sup>[2]</sup>. Numerous studies have shown that *H. pylori* is the major cause of stomach inflammation, and it is recognized as a key factor in the development of upper gastrointestinal tract pathologies including peptic ulcer disease, gastric cancer, extragastric intestinal malignancies and gastric mucosal-associated lymphoid tissue lymphoma<sup>[3-10]</sup>.

Among the known *H. pylori* virulence factors that include cytotoxin-associated gene A product (CagA), vacuolating cytotoxin (VacA), outer inflammatory pro-

**Table 1** Detection of *Helicobacter pylori* in investigations of relationships between *Helicobacter pylori* and rhinitis/sinusitis

| Ref.                                      | Patients (n) | Samples                           | Methods                     | Positive results |
|---|--------------|-----------------------------------|-----------------------------|------------------|
| <b>Rhinitis</b>                           |              |                                   |                             |                  |
| Cellini <i>et al</i> <sup>[43]</sup>      | 42           | Nasal mucus                       | Culture                     | 0%               |
| Imamura <i>et al</i> <sup>[44]</sup>      | 211          | Blood                             | ELISA                       | 44.8%            |
| <b>Sinusitis</b>                          |              |                                   |                             |                  |
| Ozyurt <i>et al</i> <sup>[52]</sup>       | 32           | Nasal polyp                       | PCR                         | 59.4%            |
| Szczygielski <i>et al</i> <sup>[53]</sup> | 61           | Nasal polyp                       | Urease test                 | 0%               |
| Kaviani <i>et al</i> <sup>[54]</sup>      | 37           | Nasal polyp                       | Urease test                 | 24.3%            |
|   |              | Blood                             | ELISA (IgG)                 | 66.2%            |
| Cvorovic <i>et al</i> <sup>[55]</sup>     | 23           | Nasal polyp                       | Urease test/giemsa staining | 26.1%            |
| Včeva <i>et al</i> <sup>[57]</sup>        | 35           | Nasal polyp                       | PCR                         | 28.6%            |
|   |              | Blood                             | ELISA                       | 85.7%            |
| Burduk <i>et al</i> <sup>[58]</sup>       | 30           | Nasal polyp                       | PCR                         | 100%             |
| Morinaka <i>et al</i> <sup>[59]</sup>     | 11           | Nasal and maxillary sinus tissues | PCR                         | 18.2%            |
|   |              |                                   | Urease test                 | 27.3%            |
|   |              |                                   | Culture                     | 0%               |
|   |              |                                   | IHC                         | 63.6%            |
| Ozdek <i>et al</i> <sup>[60]</sup>        | 12           | Ethmoid mucosa                    | PCR                         | 33.3%            |
| Koc <i>et al</i> <sup>[61]</sup>          | 30           | Nasal polyp                       | IHC                         | 20%              |
|   |              | Blood                             | ELISA                       | 86.7%            |
| Kim <i>et al</i> <sup>[62]</sup>          | 48           | Intranasal tissue                 | Urease test/IHC             | 25%              |
| Jelavic <i>et al</i> <sup>[63]</sup>      | 40           | Nasal polyp                       | IHC                         | 70%              |
| Ozcan <i>et al</i> <sup>[64]</sup>        | 25           | Nasal polyp                       | Urease test                 | 4%               |
|   |              |                                   | IHC                         | 0%               |
|   |              | Blood                             | ELISA                       | 24%              |
| Dinis <i>et al</i> <sup>[71]</sup>        | 15           | Sinonasal tissue                  | PCR                         | 19%              |
| Nemati <i>et al</i> <sup>[72]</sup>       | 25           | Nasal polyp                       | PCR                         | 0%               |
|   |              |                                   | Culture                     | 0%               |
|   |              |                                   | Urease test                 | 0%               |

IHC: Immunohistochemistry; ELISA: Enzyme-linked immunosorbent assay; PCR: Polymerase chain reaction.

tein and duodenal ulcer promoting<sup>[11]</sup>, VacA and CagA have been the most thoroughly investigated in an effort to understand the pathogenicity of this bacterium. VacA is a pore-forming toxin that disrupts cell polarity in the gastric mucosa, promotes the apoptosis of epithelial cells, and inhibits T cell proliferation. CagA is an immunodominant antigen that is translocated into gastric epithelial cells through the Cag type IV secretion system encoded by *cag* pathogenicity islands<sup>[12]</sup>. *H. pylori* strains that express CagA are associated with an increased risk of gastric cancer. In addition to these local interactions, *H. pylori* impairs T cell-mediated immunity *via* systemic mechanisms<sup>[13]</sup>.

Systemic immune and inflammatory responses to *H. pylori* might be related to extra-gastrointestinal system diseases<sup>[13]</sup>. Recent studies have identified a potential relationship between *H. pylori* infection and the pathogenesis of cardiovascular, neurological, dermatological, immunological, hematological, hepatobiliary, ophthalmological and gynecological diseases, as well as diabetes mellitus<sup>[14-23]</sup>. A role of *H. pylori* in the development of lower respiratory disease has also been suggested, but a

pathophysiological association has not been proven<sup>[24-28]</sup>.

The impact of gastric *H. pylori* infection on the pathogenesis of gastroesophageal reflux disease (GERD) is controversial<sup>[29,30]</sup>, but *H. pylori* can survive for a certain period in gastric juice in the esophagus<sup>[31]</sup>. Gastric juices infected with *H. pylori* and systemic immune responses to gastric *H. pylori* infection might play a causative role in upper respiratory diseases<sup>[32-34]</sup>. In contrast, the findings of recent cross-sectional studies indicate that the risk of developing childhood- or early-onset allergic asthma, allergic rhinitis and atopic dermatitis is decreased in carriers of *H. pylori* compared with non-infected individuals<sup>[35-40]</sup>, indicating that *H. pylori* can have both harmful and beneficial effects in patients with upper respiratory diseases.

Although the pathogenicity of *H. pylori* in gastrointestinal lesions has been extensively studied, the role of this bacterium in upper respiratory tract disorders is under debate. The present review summarizes current findings regarding the relationship between *H. pylori* and upper respiratory tract diseases.

## RHINITIS

Allergic rhinitis is the most widespread type of chronic rhinitis, and it is the typical type I, immunoglobulin (Ig) E (IgE) antibody-mediated, hypersensitive response of the nasal mucosa to environmental allergens for all age groups<sup>[41]</sup>. Allergic rhinitis and asthma are pathologically similar, and mucosal inflammation including the production of inflammatory factors (cytokines, adhesion molecules and inflammatory mediators) in allergic rhinitis is similar to that associated with bronchial asthma. In addition, allergic rhinitis is an independent risk factor for the development of asthma<sup>[41,42]</sup>. *H. pylori* is not always detectable in the nasal secretions of patients with gastric *H. pylori*<sup>[43]</sup> (Table 1), yet an inverse association between *H. pylori* infection and allergic rhinitis has been reported. An investigation into the association between the prevalence of *H. pylori* and pollinosis symptoms in healthy volunteers and the relationship between serum *H. pylori*-IgG and specific IgE antibodies for pollen, mites and house dust in 211 consecutive patients concluded that *H. pylori* infection might play an important role in protecting against the development of pollinosis, especially among younger patients<sup>[44]</sup>. The findings of a cross-sectional analysis of data from 7412 participants in the National Health and Nutrition Examination Survey 1999-2000 similarly showed that *H. pylori* seropositivity is inversely related to recent wheezing, allergic rhinitis, and dermatitis, eczema, or rash<sup>[37]</sup>. One possible explanation for these findings is the hygiene hypothesis<sup>[45]</sup>. Although definitive mechanisms remain unknown and contradictory opinions have been published<sup>[46,47]</sup>, a protective role of *H. pylori* against allergic disorders including allergic rhinitis and asthma is biologically plausible.

Non-allergic rhinitis is also known as idiopathic, irritant-induced, and vasomotor rhinitis. Non-allergic rhinitis is a heterogeneous condition that has been classified in

**Table 2** Detection of *Helicobacter pylori* in investigations of relationships between *Helicobacter pylori* and adenoiditis/adenoid hyperplasia

| Ref.  | Patients<br>( <i>n</i> ) | Samples                  | Methods     | Positive<br>results |
|---|--------------------------|--------------------------|-------------|---------------------|
| Unver <i>et al</i> <sup>[73]</sup>          | 12                       | Adenoid tissue           | Urease test | 25%                 |
| Khademi<br><i>et al</i> <sup>[74]</sup>     | 56                       | Adenotonsillar<br>tissue | Urease test | 48%                 |
| Farhadi <i>et al</i> <sup>[75]</sup>        | 40                       | Adenoid tissue<br>Blood  | PCR         | 15%                 |
|   |                          |                          | ELISA (IgG) | 20%                 |
|   |                          |                          | ELISA (IgA) | 17.5%               |
| Eyigor <i>et al</i> <sup>[76]</sup>         | 47                       | Adenotonsillar<br>tissue | Urease test | 5.5%                |
|   |                          |                          | PCR         | 0%                  |
| Cirak <i>et al</i> <sup>[77]</sup>          | 10                       | Adenoid tissue           | PCR         | 30%                 |
| Abdel-Monem<br><i>et al</i> <sup>[80]</sup> | 10                       | Adenoid tissue<br>Blood  | Urease test | 40%                 |
|   |                          |                          | PCR         | 20%                 |
|   |                          |                          | ELISA       | 20%                 |
| Bulut <i>et al</i> <sup>[81]</sup>          | 71                       | Adenotonsillar<br>tissue | Urease test | 13.6%               |
|   |                          |                          | PCR         | 24.6%               |
| Vilarinho<br><i>et al</i> <sup>[82]</sup>   | 55                       | Adenoid tissue           | Urease test | 3.6%                |
|   |                          |                          | IHC         | 0%                  |
|   |                          |                          | FISH        | 0%                  |
| Hussey <i>et al</i> <sup>[83]</sup>         | 78                       | Adenoid tissue           | PCR         | 0%                  |
|   |                          |                          | Histology   | 0%                  |
|   |                          |                          | PCR         | 0%                  |
| Vayisoglu<br><i>et al</i> <sup>[84]</sup>   | 60                       | Adenoid tissue<br>Blood  | Urease test | 3.3%                |
|   |                          |                          | IHC         | 3.3%                |
|   |                          |                          | ELISA (IgG) | 13.3%               |
| Bitar <i>et al</i> <sup>[85]</sup>          | 25                       | Adenoid tissue           | ELISA (IgA) | 3.3%                |
|   |                          |                          | Urease test | 84%                 |
|   |                          |                          | Histology   | 16%                 |
| Bitar <i>et al</i> <sup>[86]</sup>          | 18                       | Adenoid tissue           | PCR         | 0%                  |
|   |                          |                          | Urease test | 72.2%               |
| Pitkäranta<br><i>et al</i> <sup>[87]</sup>  | 20                       | Adenoid tissue           | Culture     | 0%                  |
|   |                          | Fecal samples            | ELISA       | 20%                 |
| Toros <i>et al</i> <sup>[88]</sup>          | 84                       | Adenoid tissue           | Urease test | 0%                  |
|   |                          |                          | Histology   | 0%                  |
| Ozcan <i>et al</i> <sup>[89]</sup>          | 19                       | Adenoid tissue           | Urease test | 0%                  |
|   |                          |                          | IHC         | 0%                  |
| Fancy <i>et al</i> <sup>[90]</sup>          | 45                       | Adenoid tissue           | PCR         | 22.2%               |
| Yilmaz <i>et al</i> <sup>[91]</sup>         | 42                       | Adenoid tissue           | Culture     | 28.6%               |
|   |                          |                          | PCR         | 47.6%               |
| Yilmaz <i>et al</i> <sup>[92]</sup>         | 38                       | Adenoid tissue           | PCR         | 2.6%                |
| Agirdir <i>et al</i> <sup>[93]</sup>        | 30                       | Adenoid tissue           | Urease test | 33.3%               |
| Park <i>et al</i> <sup>[96]</sup>           | 62                       | Adenoid tissue           | PCR         | 14.5%               |

ELISA: Enzyme-linked immunosorbent assay; FISH: Fluorescence *in situ* hybridization; IHC: Immunohistochemistry; PCR: Polymerase chain reaction.

many ways. Because of the complexity of pathophysiological mechanisms in non-allergic rhinitis, this condition remains undefined and consensus regarding a management strategy has not been reached<sup>[48]</sup>. To the best of our knowledge, the relationship between non-allergic rhinitis and *H. pylori* and the role of *H. pylori* in acute rhinitis have never been investigated.

## SINUSITIS

Chronic rhinosinusitis is defined as a persistent inflammatory response involving the mucous membranes of the nasal cavity and paranasal sinuses. It is usually diagnosed based on having at least two of the following characteris-

tic symptoms: nasal congestion, facial pain/pressure, anterior or posterior nasal drainage, reduced or no sense of smell and persisting for > 12 wk, together with objective evidence of sinus disease determined by direct visualization or imaging<sup>[49-51]</sup>.

*H. pylori* and the *cagA* gene have frequently been detected in nasal polyp specimens and the inflamed mucosa of the paranasal sinus in patients with chronic rhinosinusitis<sup>[52-58]</sup> (Table 1). *H. pylori* might play a positive role in chronic rhinosinusitis<sup>[59,60]</sup>. The prevalence of sinonasal *H. pylori* is higher in patients with, than without chronic rhinosinusitis<sup>[61,62]</sup>. Recent functional endoscopic sinus surgery for patients with chronic rhinosinusitis revealed that postoperative endoscopic scores improved significantly more among patients with chronic rhinosinusitis and *H. pylori* sinonasal colonization<sup>[63]</sup>.

Contradictory opinions regarding the role of *H. pylori* in chronic rhinosinusitis have also been published. Ozcan *et al*<sup>[64]</sup> reported that infection with *H. pylori* is only transient, and that such infection could not possibly be an etiological factor for nasal polyposis. Furthermore, Lund-MacKay computed tomography and symptom scores did not indicate a significant correlation between intranasal *H. pylori* colonization and the preoperative severity of chronic rhinosinusitis<sup>[62]</sup>.

Gastro-esophageal reflux might play a role in the pathogenesis of chronic rhinosinusitis<sup>[65-70]</sup>. Although pepsin/pepsinogen has been detected in sinonasal samples<sup>[71]</sup>, others did not find a significant association between *H. pylori* in nasal polyps and nasal polyposis in patients without signs or symptoms of GERD<sup>[72]</sup>. These findings suggest that gastric juice infected with *H. pylori* and not *H. pylori* itself is involved in the development of chronic rhinosinusitis.

Chronic as well as allergic fungal rhinosinusitis can exist with or without nasal polyps, and sinusitis also includes acute rhinosinusitis<sup>[49,50]</sup>. Further studies are needed to identify the roles of *H. pylori* in the etiology of each subtype of sinusitis.

## ADENOIDITIS AND ADENOID HYPERPLASIA

Adenoiditis is acute or chronic inflammation of the pharyngeal tonsils (adenoids). Adenoid hypertrophy, also termed adenoid hyperplasia or enlarged adenoids, is the unusual, non-tumorous, growth of the adenoid tissue.

Early studies used the rapid urease test (also known as the campylobacter-like organism test; CLO test) to detect *H. pylori* in adenoid tissues<sup>[73,74]</sup> (Table 2). Recent studies have applied the polymerase chain reaction (PCR) to detect *H. pylori* in adeno-tonsillar tissue specimens<sup>[75-77]</sup>. Exposure to an unsuitable environment can induce this organism to enter a viable but non-culturable state and to persist in the environment until it enters a suitable host<sup>[78,79]</sup>. Because of the characteristics, culturing the *H. pylori* organism from the samples of upper respiratory tract can be difficult, and thus can have low sensitivity<sup>[80]</sup>.

**Table 3** Detection of *Helicobacter pylori* in clinical investigations of relationships between *Helicobacter pylori* and otitis media

| Ref.                                    | Patients (n) | Samples           | Methods     | Positive results |
|---|--------------|-------------------|-------------|------------------|
| Bitar <i>et al</i> <sup>[86]</sup>      | 28           | Middle ear fluid  | Culture     | 0%               |
| Pitkäranta <i>et al</i> <sup>[87]</sup> | 20           | Middle ear fluid  | Culture     | 0%               |
| Ozcan <i>et al</i> <sup>[89]</sup>      | 25           | Middle ear fluid  | Urease test | 0%               |
|   |              | Blood             | ELISA (IgG) | 32%              |
|   |              |                   | ELISA (IgA) | 12%              |
| Fancy <i>et al</i> <sup>[90]</sup>      | 45           | Middle ear fluid  | PCR         | 32%              |
| Yilmaz <i>et al</i> <sup>[91]</sup>     | 22           | Middle ear fluid  | Culture     | 9%               |
|   |              |                   | PCR         | 31.8%            |
|   |              | Middle ear mucosa | Culture     | 4.5%             |
|   |              |                   | PCR         | 27.3%            |
| Yilmaz <i>et al</i> <sup>[92]</sup>     | 18           | Middle ear fluid  | PCR         | 66.7%            |
| Agirdir <i>et al</i> <sup>[93]</sup>    | 45           | Middle ear fluid  | Urease test | 66.6%            |
| Morinaka <i>et al</i> <sup>[94]</sup>   | 15           | Middle ear fluid  | Urease test | 20%              |
|   |              |                   | IHC         | 80%              |
| Karlıdag <i>et al</i> <sup>[95]</sup>   | 38           | Middle ear fluid  | PCR         | 16.3%            |
| Park <i>et al</i> <sup>[96]</sup>       | 60           | Middle ear fluid  | Urease test | 26.7%            |
|   |              |                   | PCR         | 33.3%            |
| Bai <i>et al</i> <sup>[97]</sup>        | 60           | Middle ear fluid  | PCR         | 40%              |
|   |              |                   | Culture     | 11.7%            |
|   |              |                   | Urease test | 11.7%            |
| Kutluhan <i>et al</i> <sup>[101]</sup>  | 38           | Middle ear tissue | PCR         | 7.9%             |
| Dagli <i>et al</i> <sup>[102]</sup>     | 41           | Middle ear mucosa | Urease test | 53.6%            |

ELISA: Enzyme-linked immunosorbent assay; IHC: Immunohistochemistry; PCR: Polymerase chain reaction.

A comparison of the sensitivity and specificity of the rapid urease test, PCR and blood serology to detect *H. pylori* in the adenotonsillar tissue of symptomatic children with chronic adenotonsillitis found that PCR is the most reliable method of detecting *H. pylori* infection<sup>[80]</sup>.

Several studies have detected *H. pylori* in adenoids and considered that the adenoids might serve as an ecological niche and as an extra-gastric reservoir for *H. pylori*<sup>[73-77,80,81]</sup>. However, contradictory opinions have also been expressed<sup>[82-84]</sup>. An analysis of 78 pediatric patients concluded that adenoid inflammation and enlargement are probably not due to ongoing *H. pylori* infection<sup>[83]</sup>. In addition, some authors reported that *H. pylori* has a limited (if any) role in the process of adenoid disease<sup>[85-90]</sup>. The pathophysiological role of *H. pylori* in adenoid tissue remains controversial and a definitive relationship between *H. pylori* and adenoid disease has not been established.

## OTITIS MEDIA

Adenoiditis and adenoid hyperplasia are related to otitis media. We searched the English literature and found 11 original research studies of human samples and one systematic review describing the relationship between *H. pylori* and otitis media with effusion<sup>[86,87,89-98]</sup> (Table 3). In addition, two clinical studies investigated *H. pylori* in patients with chronic otitis media, and two studies examined the role of *H. pylori* in experimental animal models of otitis

media<sup>[99-102]</sup>.

*H. pylori* was detected in middle ear effusions in 8 of 11 clinical studies of otitis media with effusion<sup>[90-97]</sup>. On the other hand, cultures of middle ear fluid were all negative for *H. pylori* and CLO test results were also negative in another study of middle ear effusions<sup>[86,87,89]</sup>. Because *H. pylori* is difficult to detect in culture, its presence in middle ear effusions of some, but not all, patients with otitis media with effusion might be assumed. The next issue is whether *H. pylori* plays a role in the etiology of otitis media with effusion. Agirdir *et al*<sup>[93]</sup> collected middle ear effusions from 30 pediatric patients with otitis media with effusion, and washed the middle ears of 15 age-matched patients without middle ear effusion. They detected *H. pylori* in 20 (66.6%) patients with otitis media with effusion, but not in washes of the middle ears of patients without middle ear effusion according to the CLO. A PCR-based study of aspiration samples collected from 60 adult patients showed that 24 (40%) were *H. pylori*-positive<sup>[97]</sup>. These findings suggest that *H. pylori* could be responsible for the etiopathogenesis of otitis media with effusion. However, the relationship between *H. pylori* and otitis media with effusion remains controversial.

The CLO test and nested PCR of middle ear tissue samples found that 53.6% and 7.9%, respectively, of patients with chronic otitis media were positive for *H. pylori*<sup>[101,102]</sup>. The role of *H. pylori* in chronic otitis media is presently under investigation.

Live *H. pylori* or physiological saline was added to the middle ear cavities of New Zealand white rabbits with histamine-induced otitis media. A further injection of live *H. pylori* induced accelerated inflammation in the middle ear compared with animals that had been injected with histamine<sup>[99]</sup>. Another study found that the direct injection of protein extracted from whole cell sonicates of *H. pylori* (American Type Culture Collection) into the middle ear of mice induced the up-regulation of inflammatory cytokines (macrophage migration inhibitory factor, macrophage inflammatory protein 2, interleukin-1 $\beta$  and tumor necrosis factor- $\alpha$ ), as well as the severe proliferation of inflammatory cells in middle ear epithelium<sup>[100]</sup>. These findings suggest that *H. pylori* plays a role in the development of middle ear inflammation, even if the bacterium is not live.

Particularly among children, acute otitis media is a common disease that is most often caused by *Streptococcus pneumoniae*, nontypeable *Haemophilus influenzae*, and *Moraxella catarrhalis*<sup>[103]</sup>. We could not find any publications in the English literature describing the relationship between *H. pylori* infection and acute otitis media.

## ORAL DISEASES

Numerous authors have reported the presence<sup>[104-109]</sup> or absence<sup>[110-114]</sup> of *H. pylori* in the oral cavity, especially in dental plaque, which is formed by colonizing bacteria attempting to attach to the smooth surface of teeth<sup>[115-121]</sup> (Table 4). The prevalence of gastric *H. pylori* infection



**Table 4** Detection of *Helicobacter pylori* in studies with large samples that investigated relationships between *Helicobacter pylori* and oral diseases

| Ref.                                    | Patients (n) | Samples                  | Methods     | Positive results |
|---|--------------|--------------------------|-------------|------------------|
| Bernander et al <sup>[110]</sup>        | 94           | Dental plaque            | Culture     | 0%               |
| Luman et al <sup>[113]</sup>            | 120          | Saliva and dental plaque | Culture     | 0%               |
| Chaudhry et al <sup>[118]</sup>         | 89           | Dental plaque            | PCR         | 51.6%            |
| Butt et al <sup>[119]</sup>             | 178          | Dental plaque            | Urease test | 100%             |
| Sudhakar et al <sup>[121]</sup>         | 50           | Dental plaque            | Culture     | 10%              |
|   |              |                          | Urease test | 70%              |
| Assumpção et al <sup>[126]</sup>        | 99           | Dental plaque            | PCR         | 72%              |
|   | 93           |                          | Urease test | 52%              |
| Gao et al <sup>[127]</sup>              | 96           | Dental plaque            | PCR         | 82.3%            |
| Fernández-Tilapa et al <sup>[143]</sup> | 200          | Saliva and dental plaque | PCR         | 17%              |
|   |              | Blood                    | ELISA       | 62%              |
| Eskandari et al <sup>[144]</sup>        | 67           | Dental plaque            | PCR         | 5.9%             |
| Karczewska et al <sup>[145]</sup>       | 329          | Gingival pocket material | Culture     | 50%              |
|   |              |                          | PCR         | 35%              |
| Oshowo et al <sup>[150]</sup>           | 208          | Dental plaque            | PCR         | 7.2%             |
|   |              |                          | Culture     | 0.9%             |
|   |              | Tongue scraping          | PCR         | 0%               |
|   |              |                          | Culture     | 0%               |
| Gall-Troselj et al <sup>[174]</sup>     | 268          | Tongue mucosa            | PCR         | 16%              |
| Suzuki et al <sup>[177]</sup>           | 326          | Saliva                   | PCR         | 6.2%             |

ELISA: Enzyme-linked immunosorbent assay; PCR: Polymerase chain reaction.

was significantly higher among 443 dyspeptic patients with dental plaque that was positive, than negative for *H. pylori*<sup>[122]</sup>.

*H. pylori* usually spreads *via* the fecal-oral route, and possibly by the oral-oral route and the spread of contaminated secretions<sup>[31,79,123-125]</sup>. An investigation of *H. pylori* genotypes in saliva, dental plaques, stools and gastric biopsy samples from 300 patients found that the fecal-oral route was the main method of *H. pylori* transmission. Furthermore, the oral cavity might serve as a reservoir for *H. pylori* because the genotypes of *H. pylori* isolates from saliva, stomach and stool are similar<sup>[126-129]</sup>. Debate continues regarding whether or not the oral cavity is the major reservoir of *H. pylori* for gastric re-infection<sup>[130-139]</sup>. Although some investigators have reported that the oral cavity is the reservoir for *H. pylori*<sup>[140-151]</sup>, insufficient evidence supports the notion that dental treatment can prevent recurrent gastric *H. pylori* infection<sup>[152]</sup>.

Aphthous stomatitis is the most common oral mucosal disease that causes small ulcers in the mouth, usually inside the lips, on the cheeks, or on the tongue and *H. pylori* might be an important factor in the recurrence of this condition<sup>[153-158]</sup>. However, conflicting findings have been reported<sup>[159-166]</sup>. A study of 36 consecutive patients affected by minor and major forms of recurrent aphthous stomatitis and 48 healthy volunteers found that *H. pylori* is not involved in recurrent aphthous stomatitis<sup>[167]</sup>. A recent systematic review has also shown that the pathogenesis of recurrent aphthous stomatitis and *H. pylori* are not associated<sup>[168]</sup>.

A relationship with *H. pylori* has been investigated

among various oral disorders including periodontal disease<sup>[169-173]</sup>, glossitis, burning mouth syndrome<sup>[174]</sup>, halitosis<sup>[175-177]</sup>, Behçet's syndrome<sup>[178]</sup>, lichen planus<sup>[179,180]</sup>, and taste perception<sup>[181]</sup>. Combining periodontal with systemic therapy might be a promising approach to improving therapeutic effects and decreasing the risk of recurrent gastric infection<sup>[182]</sup>. However, an association between *H. pylori* and various periodontal disorders has not been established.

*H. pylori* might comprise part of the normal oral microflora<sup>[105]</sup>. *H. pylori* in dental plaque might not be associated with brushing frequency and oral health status and one study of 161 patients concluded that *H. pylori* is not pathogenic in the oral cavity<sup>[183-185]</sup>.

In conclusion, whether or not *H. pylori* in the oral cavity plays a pathogenic role remains debatable. Nonetheless, dentists and dental professionals are at increased risk of exposure to *H. pylori* through contact with the oral cavities of infected patients<sup>[186,187]</sup>.

## TONSILLITIS AND TONSIL HYPERTROPHY

Chronic tonsillitis is a common condition characterized by persistent inflammation of the palatine tonsils, and bacterial infection is usually the cause. Idiopathic tonsillar hypertrophy presents without a history of infection and sometimes leads to obstructive sleep apnea and dysphagia.

*H. pylori* is detectable in tonsillar tissues and viable *H. pylori* can colonize these tissues<sup>[188-193]</sup> (Table 5). In addition, *H. pylori* has been identified in both tonsillar surface and core tissues<sup>[194,195]</sup>. A histopathological assessment of tonsillar tissues found that 130 (39.6%) of 285 children were positive for *H. pylori* and that the rapid urease test was not sensitive enough as a diagnostic tool<sup>[191]</sup>. A single method alone might not be sufficiently reliable to detect *H. pylori* in the tonsils, and thus, a combination of diagnostic methods could be recommended<sup>[196]</sup>.

The rate of *H. pylori* infection was significantly higher in tonsillar tissues from a group of patients with tonsillitis compared with a group who had sleep-related breathing disorders (48% *vs* 24%)<sup>[197]</sup>. In contrast, another study found no significant difference between the incidence of *H. pylori*-positive tonsillar samples from patients with chronic tonsillitis and those with obstructive sleep apnea syndrome (80% *vs* 83%)<sup>[193]</sup>. Regardless, the high incidence of *H. pylori* infection in tonsil tissue indicates that tonsillectomy might impact gastric infection with this bacterium. A multiple regression analysis of confounding variables in patients with *H. pylori* gastric infection revealed that a history of tonsillectomy is associated with a decreased prevalence of gastric *H. pylori*<sup>[198]</sup>. In contrast, another report indicated that tonsillar tissue does not seem to be a reservoir for *H. pylori* infection and that tonsillectomy does not significantly affect gastric *H. pylori* eradication; however, the results might have been skewed by a relatively small sample size<sup>[199]</sup>. A comparison of genotypes between oropharyngeal and gastric *H. pylori*

**Table 5** Detection of *Helicobacter pylori* in clinical investigations of relationships between *Helicobacter pylori* and tonsillitis/tonsil hypertrophy

| Ref.   | Patients (n) | Samples               | Methods     | Positive results |
|--|--------------|-----------------------|-------------|------------------|
| Unver <i>et al</i> <sup>[73]</sup>           | 16           | Tonsillar tissue      | Urease test | 62.5%            |
| Cirak <i>et al</i> <sup>[77]</sup>           | 22           | Tonsillar tissue      | PCR         | 18.2%            |
| Abdel-Monem <i>et al</i> <sup>[80]</sup>     | 20           | Tonsillar tissue      | Urease test | 60%              |
|  |              |                       | PCR         | 15%              |
|  |              | Blood                 | ELISA       | 20%              |
| Najafipour <i>et al</i> <sup>[188]</sup>     | 103          | Tonsillar tissue      | Urease test | 48.5%            |
|  |              |                       | PCR         | 19.4%            |
| Farivar <i>et al</i> <sup>[189]</sup>        | 103          | Tonsillar tissue      | PCR         | 21.4%            |
|  |              |                       | Histology   | 18.4%            |
| Jabbari                                      | 285          | Tonsillar tissue      | Histology   | 39.6%            |
| Moghaddam <i>et al</i> <sup>[191]</sup>      |              |                       | Urease test | 14.0%            |
|  |              | Blood                 | ELISA       | 5.2%             |
| Wibawa <i>et al</i> <sup>[192]</sup>         | 19           | Tonsillar tissue      | Culture     | 15.7%            |
| Nártová <i>et al</i> <sup>[193]</sup>        | 89           | Tonsillar tissue      | PCR         | 80.9%            |
| Khademi <i>et al</i> <sup>[194]</sup>        | 55           | Adenotonsillar tissue | Urease test | 82%              |
| Aslan <i>et al</i> <sup>[195]</sup>          | 52           | Tonsil core tissue    | Urease test | 47%              |
|  |              | Mucosal tissue        | Urease test | 42%              |
|  |              | Tonsillar tissue      | Histology   | 0%               |
| Lin <i>et al</i> <sup>[197]</sup>            | 94           | Tonsillar tissue      | Urease test | 35%              |
| Kusano <i>et al</i> <sup>[201]</sup>         | 173          | Tonsillar tissue      | IHC         | 72.8%            |
| Kusano <i>et al</i> <sup>[202]</sup>         | 55           | Tonsillar tissue      | IHC         | 78.2%            |
| Yilmaz <i>et al</i> <sup>[203]</sup>         | 50           | Blood                 | ELISA       | 56%              |
|  |              | Stool                 | ELISA       | 50%              |
|  |              | Tonsillar tissue      | Urease test | 0%               |
| Skinner <i>et al</i> <sup>[204]</sup>        | 50           | Blood                 | ELISA       | 28%              |
|  |              | Tonsillar tissue      | Urease test | 0%               |
| Jelavic <i>et al</i> <sup>[205]</sup>        | 77           | Blood                 | ELISA       | 79%              |
|  |              | Tonsillar tissue      | Urease test | 12%              |
| di Bonaventura <i>et al</i> <sup>[206]</sup> | 72           | Tonsillar swab        | Culture     | 0%               |
|  |              |                       | IHC         | 0%               |
| Di Bonaventura <i>et al</i> <sup>[207]</sup> | 72           | Tonsillar tissue      | PCR         | 0%               |

ELISA: Enzyme-linked immunosorbent assay; IHC: Immunohistochemistry; PCR: Polymerase chain reaction.

isolates from six patients revealed important differences within each individual<sup>[200]</sup>. Although the sample size was very small, these findings suggest that tonsils do not comprise a reservoir for gastric *H. pylori* infection, and that more than one *H. pylori* strain can exist in the oropharynx and stomach of the same patient.

Coccoid *H. pylori* isolated from the tonsillar tissues of patients with IgA nephropathy is one causative antigen of this disease<sup>[201,202]</sup>. A relationship between *H. pylori* and acute tonsillitis has not been reported.

Although a possible role for *H. pylori* residing in the tonsils has been indicated, other studies have not detected *H. pylori* in specimens of adenotonsillectomy, and have not found that tonsillar tissues constitute a reservoir for *H. pylori* infection<sup>[203-207]</sup>. The disparity might be due to a difference in sample populations and methodology.

## PHARYNGEAL DISEASES

Acute or chronic pharyngitis is defined as inflammation of the mucous membranes and submucosal tissues of

**Table 6** Detection of *Helicobacter pylori* in investigations of relationships between *Helicobacter pylori* and benign pharyngeal/laryngeal diseases

| Ref.  | Patients (n) | Samples           | Methods     | Positive results |
|---|--------------|-------------------|-------------|------------------|
| Pharyngeal disease                          |              |                   |             |                  |
| Aladag <i>et al</i> <sup>[208]</sup>        | 41           | Blood             | ELISA       | 78%              |
| Zhang <i>et al</i> <sup>[211]</sup>         | 50           | Pharyngeal tissue | Histology   | 38%              |
| Kaptan <i>et al</i> <sup>[212]</sup>        | 70           | Pharyngeal tissue | PCR         | 27.1%            |
|   |              |                   | Culture     | 5.8%             |
| Elsheikh <i>et al</i> <sup>[213]</sup>      | 146          | Pharyngeal tissue | PCR         | 32.9%            |
| Laryngeal disease                           |              |                   |             |                  |
| Ozyurt <i>et al</i> <sup>[52]</sup>         | 27           | Laryngeal tissue  | PCR         | 58.6%            |
| Burdak <i>et al</i> <sup>[58]</sup>         | 30           | Laryngeal tissue  | PCR         | 100%             |
| Cekin <i>et al</i> <sup>[215]</sup>         | 43           | Laryngeal tissue  | PCR         | 55.8%            |
| Youssef <i>et al</i> <sup>[217]</sup>       | 212          | Stool             | ELISA       | 57.5%            |
| Rubin <i>et al</i> <sup>[222]</sup>         | 101          | Blood             | ELISA       | 54.5%            |
| Talaat <i>et al</i> <sup>[223]</sup>        | 162          | Stool             | ELISA       | 86.4%            |
| Tiba M <i>et al</i> <sup>[224]</sup>        | 14           | Laryngeal tissue  | PCR         | 71.4%            |
|   |              |                   | IHC         | 71.4%            |
| Borkowski <i>et al</i> <sup>[226]</sup>     | 35           | Laryngeal tissue  | Urease test | 17.1%            |
| Siupsinskiene <i>et al</i> <sup>[227]</sup> | 54           | Laryngeal tissue  | Urease test | 37.0%            |
| Jaspersen <i>et al</i> <sup>[228]</sup>     | 38           | Gastric tissue    | Urease test | 36.8%            |
|   |              | Laryngeal swab    | Culture     | 0%               |

ELISA: Enzyme-linked immunosorbent assay; IHC: Immunohistochemistry; PCR: Polymerase chain reaction.

the pharynx. The main symptom of pharyngitis is a sore throat. Several factors including nasal obstruction, chronic sinonasal infection, allergy, smoking, chronic periodontal infections, polluted air, industrial fumes, excessively hot or cold foods and alcohol consumption are associated with pharyngeal inflammation<sup>[208]</sup>. Gastroesophageal reflux is also considered an important factor in pharyngeal disorders<sup>[209,210]</sup>, and *H. pylori* residing in the pharynx might play a role in the development of pharyngitis. Some studies have tested this hypothesis by examining an association between *H. pylori* and pharyngitis (Table 6).

A prospective study of 50 patients with chronic pharyngitis found that none of the control group had *H. pylori* in the pharynx, whereas 19 (38.0%) in the group with pharyngitis were *H. pylori*-positive in template-directed dye-terminator assays with fluorescence polarization detection<sup>[211]</sup>. One study of 70 patients with chronic pharyngitis and 20 healthy controls using PCR and cultures to detect *H. pylori* colonization in pharynx mucous membranes found that none of the controls had *H. pylori* in the pharynx and that chronic nonspecific pharyngitis without gastric *H. pylori* infection was significantly related to *H. pylori* colonization in the pharynx<sup>[212]</sup>. They concluded that chronic pharyngitis might be associated with *H. pylori* infection and that gastric involvement increases the rate of pharyngeal colonization by *H. pylori*.

Another study identified a possible relationship between the prevalence of *H. pylori* DNA and recurrent aphthous ulcerations in mucosa-associated lymphoid tissues of the pharynx<sup>[213]</sup>. Acute pharyngitis is usually caused by bacterial or viral infection. To the best of our

**Table 7** Detection of *Helicobacter pylori* in investigations of relationships between *Helicobacter pylori* and head and neck malignancies

| Ref.  | Patients (n) | Samples                       | Methods     | Positive results |
|---|--------------|-------------------------------|-------------|------------------|
| Siupsinskiene <i>et al</i> <sup>[227]</sup> | 13           | Laryngeal tissue              | Urease test | 46.2%            |
| Shi <i>et al</i> <sup>[230]</sup>           | 59           | Laryngeal tissue              | PCR         | 76.3%            |
| Aygenç <i>et al</i> <sup>[231]</sup>        | 26           | Blood                         | ELISA       | 73.1%            |
| Okuda <i>et al</i> <sup>[232]</sup>         | 58           | Oral swab                     | PCR         | 100%             |
| Burduk <sup>[233]</sup>                     | 80           | Laryngeal tissue              | Urease test | 62.5%            |
| Dayama <i>et al</i> <sup>[234]</sup>        | 20           | Oral tissue                   | Culture     | 15%              |
|   |              |                               | PCR         | 15%              |
| Rubin <i>et al</i> <sup>[235]</sup>         | 53           | Blood                         | ELISA       | 64.2%            |
| Rezaei <i>et al</i> <sup>[236]</sup>        | 98           | Blood                         | ELISA       | 93.9%            |
| Gong <i>et al</i> <sup>[237]</sup>          | 81           | Laryngeal tissue              | PCR         | 71.6%            |
|   |              | Blood                         | ELISA       | 77.8%            |
| Grimm <i>et al</i> <sup>[238]</sup>         | 191          | Oral tissue                   | IHC         | 21.5%            |
| Kizilay <i>et al</i> <sup>[241]</sup>       | 69           | Laryngeal tissue              | Histology   | 0%               |
| Akbayir <i>et al</i> <sup>[242]</sup>       | 50           | Laryngeal tissue              | IHC         | 0%               |
| Pirzadeh <i>et al</i> <sup>[243]</sup>      | 65           | Laryngeal tissue              | Urease test | 0%               |
|   |              |                               | Histology   | 0%               |
| Kanda <i>et al</i> <sup>[244]</sup>         | 31           | Laryngeal tissue              | PCR         | 0%               |
|   |              |                               | Culture     | 0%               |
|   |              |                               | IHC         | 0%               |
|   |              | Urine                         | ELISA       | 67.7%            |
| Grandis <i>et al</i> <sup>[245]</sup>       | 21           | Blood                         | ELISA       | 57%              |
| Nurgalieva <i>et al</i> <sup>[246]</sup>    | 119          | Blood                         | ELISA       | 32.8%            |
| Lukeš <i>et al</i> <sup>[248]</sup>         | 11           | Oropharyngeal lymphoid tissue | Culture     | 9.1%             |
|   | 23           | Oropharyngeal lymphoid tissue | PCR         | 73.9%            |
|   | 41           | Blood                         | ELISA       | 78.1%            |
| Pavlík <i>et al</i> <sup>[249]</sup>        | 3            | Blood                         | ELISA       | 0%               |
|   |              | Tonsillar tissue              | PCR         | 100%             |

ELISA: Enzyme-linked immunosorbent assay; PCR: Polymerase chain reaction.

knowledge, a causative role of *H. pylori* in acute pharyngitis has never been reported. The etiological role of *H. pylori* in pharyngeal diseases remains obscure. Further studies are needed to understand the pathogenic role of *H. pylori* in the pharynx.

## LARYNGEAL DISEASES

The impact of gastric juice with low pH on laryngeal disorders has been reported<sup>[214]</sup>. Both laryngopharyngeal and gastroesophageal reflux might cause laryngopharyngeal symptoms, and laryngopharyngeal reflux has been identified in 50.4% (57/113) of patients with laryngeal and voice disorders<sup>[215-221]</sup>. Laryngopharyngeal reflux is involved in the pathogenesis of several laryngeal disorders, including chronic posterior laryngitis, vocal fold nodules, paroxysmal laryngospasm, Reinke's edema, laryngeal true vocal fold ulcers and granuloma as well as globus sensation<sup>[216]</sup>.

The larynx could be directly exposed to *H. pylori* as a result of pharyngolaryngeal reflux, and gastric *H. pylori* infection might be associated with disorders of the larynx<sup>[52,222]</sup> (Table 6). One study found more prevalent *H. pylori* infection among 162 patients who presented

mainly with chronic, persistent cough of unidentifiable causes compared with controls and that the eradication of *H. pylori* significantly improved patient symptomatology<sup>[223]</sup>. Another study found that patients with minimal vocal fold lesions (vocal fold polyps and nodules, and posterior granulomas) were commonly positive for *H. pylori* and that its eradication should be considered when presented with such lesions<sup>[224]</sup>. A PCR study detected *H. pylori* DNA (*ureA* gene) in samples from all of 30 patients with benign larynx diseases (polyps and Reinke's edema) and the *H. pylori cagA* gene was identified in 7 (23.3%) of them<sup>[58]</sup>.

Laryngitis is inflammation of the larynx due to various factors<sup>[225]</sup>. Some clinical studies have shown a possible role for *H. pylori* in the etiology of chronic laryngitis<sup>[226,227]</sup>. The positive rates of *H. pylori* in laryngeal samples from patients with vocal cord polyps and laryngitis were significantly higher than the rate in control samples (32.0% and 45.5% *vs* 9.1%)<sup>[227]</sup>. In contrast, others have found no evidence to support the notion that *H. pylori* is associated with laryngitis and rather suggested that acid reflux was the underlying etiology<sup>[228]</sup>.

Presumably *H. pylori* is detectable in some laryngeal diseases. However, whether *H. pylori* plays an etiological role in the larynx has not been established due to the paucity and reliability of published studies.

## HEAD AND NECK CANCER

*H. pylori* infection causes chronic gastritis and peptic ulceration and it is the strongest risk factor for the development of gastric and colorectal cancers<sup>[8,9]</sup>. *H. pylori* might also be related to other cancers. Some epidemiological studies have shown that the odds ratios (estimated relative risks) of lung cancer with *H. pylori* infection range from 1.24 to 17.78 compared with controls, suggesting an increased risk of lung cancer in populations exposed to *H. pylori* infection, although a causal relationship between *H. pylori* and lung cancer has not been confirmed<sup>[229]</sup>. However, evidence regarding the role of *H. pylori* infection in gastrointestinal carcinogenesis suggests a relationship between *H. pylori* and malignancies of the head and neck<sup>[227]</sup>.

Several investigators have identified *H. pylori* in patients with head and neck malignancies<sup>[230-232]</sup> (Table 7). Inflammation induced by *H. pylori* would cause epithelial cell proliferation that could develop into laryngeal cancer<sup>[233]</sup>. A pilot study uncovered a possible association between *H. pylori* and an increased risk of oral cancer, and another study detected *H. pylori* antibodies in serum samples from 34 (64.2%) of 53 patients with head and neck squamous cell carcinoma (larynx, hypopharynx, tongue, tonsil, nasopharynx, and tongue base/vallecula)<sup>[234,235]</sup>. Multivariate regression analyses in two case control studies identified *H. pylori* infection as an independent risk factor for laryngopharyngeal carcinoma<sup>[236,237]</sup>. A recent study of a large patient cohort associated immunohistochemically detected *H. pylori* expression in oral squamous cell carcinoma with reduced disease-free survival<sup>[238]</sup>.



In contrast, others have not found *H. pylori* in head and neck cancers or in laryngeal carcinoma samples<sup>[239-243]</sup>. PCR, culture and immunohistochemical methods did not detect *H. pylori* in head and neck tumor tissues from 31 patients, even though 21 of them carried anti-*H. pylori* antibodies<sup>[244]</sup>. A statistically significant difference in the incidence of *H. pylori* seropositivity between patients with head and neck cancer and controls has not yet been reported and others have shown that *H. pylori* infection either protects against or promotes laryngopharyngeal carcinoma<sup>[245,246]</sup>.

The presence of *H. pylori* in head and neck tumor tissues and/or the stomach of patients with head and neck malignancies might be widespread; however, more information is required about *H. pylori* activities in patients with head and neck carcinogenesis<sup>[247-249]</sup>.

## CONCLUSION

Epidemiological studies have shown that the prevalence of carrying *H. pylori* ranges from 10%-20% to 80%-90% in developed and developing countries, respectively, and most carriers are asymptomatic<sup>[250,251]</sup>. The findings of published studies on the impact of *H. pylori* on the upper respiratory tract are inconsistent. Whether or not *H. pylori* is located in the upper respiratory tract and whether or not it plays a role in the pathogenesis of upper respiratory tract diseases remain unresolved. The risks and benefits of *H. pylori* and its role in upper respiratory disorders including cancer require urgent assessment.

## REFERENCES

- Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *Lancet* 1984; **1**: 1311-1315 [PMID: 6145023]
- Covacci A, Telford JL, Del Giudice G, Parsonnet J, Rappuoli R. Helicobacter pylori virulence and genetic geography. *Science* 1999; **284**: 1328-1333 [PMID: 10334982]
- Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GL, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. *N Engl J Med* 1991; **325**: 1132-1136 [PMID: 1891021]
- Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelstein JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma. *N Engl J Med* 1991; **325**: 1127-1131 [PMID: 1891020]
- Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, Orentreich N, Vogelstein JH, Friedman GD. Helicobacter pylori infection and gastric lymphoma. *N Engl J Med* 1994; **330**: 1267-1271 [PMID: 8145781]
- Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. *Clin Microbiol Rev* 2006; **19**: 449-490 [PMID: 16847081]
- Peterson WL. Helicobacter pylori and peptic ulcer disease. *N Engl J Med* 1991; **324**: 1043-1048 [PMID: 2005942]
- Lamb A, Chen LF. Role of the Helicobacter pylori-induced inflammatory response in the development of gastric cancer. *J Cell Biochem* 2013; **114**: 491-497 [PMID: 22961880 DOI: 10.1002/jcb.24389]
- Selgrad M, Bornschein J, Rokkas T, Malfertheiner P. Helicobacter pylori: gastric cancer and extragastric intestinal malignancies. *Helicobacter* 2012; **17** Suppl 1: 30-35 [PMID: 22958153 DOI: 10.1111/j.1523-5378.2012.00980.x]
- Shmueli H, Katicic M, Filipec Kanizaj T, Niv Y. Helicobacter pylori and nonmalignant diseases. *Helicobacter* 2012; **17** Suppl 1: 22-25 [PMID: 22958151 DOI: 10.1111/j.1523-5378.2012.00978.x]
- Yamaoka Y. Mechanisms of disease: Helicobacter pylori virulence factors. *Nat Rev Gastroenterol Hepatol* 2010; **7**: 629-641 [PMID: 20938460 DOI: 10.1038/nrgastro.2010.154]
- Delahay RM, Rugge M. Pathogenesis of Helicobacter pylori infection. *Helicobacter* 2012; **17** Suppl 1: 9-15 [PMID: 22958149 DOI: 10.1111/j.1523-5378.2012.00976.x]
- Salama NR, Hartung ML, Müller A. Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori. *Nat Rev Microbiol* 2013; **11**: 385-399 [PMID: 23652324 DOI: 10.1038/nrmicro3016]
- Radosz-Komoniewska H, Bek T, Jóźwiak J, Martirosian G. Pathogenicity of Helicobacter pylori infection. *Clin Microbiol Infect* 2005; **11**: 602-610 [PMID: 16008611]
- Figura N, Franceschi F, Santucci A, Bernardini G, Gasbarrini G, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. *Helicobacter* 2010; **15** Suppl 1: 60-68 [PMID: 21054655 DOI: 10.1111/j.1523-5378.2010.00778.x]
- Banić M, Franceschi F, Babić Z, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. *Helicobacter* 2012; **17** Suppl 1: 49-55 [PMID: 22958156 DOI: 10.1111/j.1523-5378.2012.00983.x]
- Pellicano R, Franceschi F, Saracco G, Fagoonee S, Roccarina D, Gasbarrini A. Helicobacters and extragastric diseases. *Helicobacter* 2009; **14** Suppl 1: 58-68 [PMID: 19712170 DOI: 10.1111/j.1523-5378.2009.00699.x]
- Franceschi F, Gasbarrini A. Helicobacter pylori and extragastric diseases. *Best Pract Res Clin Gastroenterol* 2007; **21**: 325-334 [PMID: 17382280]
- Suzuki H, Marshall BJ, Hibi T. Overview: Helicobacter pylori and extragastric disease. *Int J Hematol* 2006; **84**: 291-300 [PMID: 17118754 DOI: 10.1532/IJH97.06180]
- Suzuki H, Franceschi F, Nishizawa T, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. *Helicobacter* 2011; **16** Suppl 1: 65-69 [PMID: 21896088 DOI: 10.1111/j.1523-5378.2011.00883.x]
- Tan HJ, Goh KL. Extragastric manifestations of Helicobacter pylori infection: facts or myth? A critical review. *J Dig Dis* 2012; **13**: 342-349 [PMID: 22713083 DOI: 10.1111/j.1751-2980.2012.00599.x]
- Hasni SA. Role of Helicobacter pylori infection in autoimmune diseases. *Curr Opin Rheumatol* 2012; **24**: 429-434 [PMID: 22617822 DOI: 10.1097/BOR.0b013e3283542d0b]
- Papagiannakis P, Michalopoulos C, Papalexi F, Dalampoura D, Diamantidis MD. The role of Helicobacter pylori infection in hematological disorders. *Eur J Intern Med* 2013; **24**: 685-690 [PMID: 23523153]
- Malfertheiner MV, Kandulski A, Schreiber J, Malfertheiner P. Helicobacter pylori infection and the respiratory system: a systematic review of the literature. *Digestion* 2011; **84**: 212-220 [PMID: 21757913 DOI: 10.1159/000329351]
- Roussos A, Philippou N, Gourgoulis KI. Helicobacter pylori infection and respiratory diseases: a review. *World J Gastroenterol* 2003; **9**: 5-8 [PMID: 12508341]
- Roussos A, Philippou N, Mantzaris GJ, Gourgoulis KI. Respiratory diseases and Helicobacter pylori infection: is there a link? *Respiration* 2006; **73**: 708-714 [PMID: 16763382]
- Kanbay M, Kanbay A, Boyacioglu S. Helicobacter pylori infection as a possible risk factor for respiratory system disease: a review of the literature. *Respir Med* 2007; **101**: 203-209 [PMID: 16759841]
- Wang Q, Yu C, Sun Y. The association between asthma and Helicobacter pylori: a meta-analysis. *Helicobacter* 2013; **18**: 41-53 [PMID: 23067334 DOI: 10.1111/hel.12012]
- Bredenoord AJ, Pandolfino JE, Smout AJ. Gastro-oesophageal reflux disease. *Lancet* 2013; **381**: 1933-1942 [PMID: 23477993 DOI: 10.1016/S0140-6736(12)62171-0]



- 30 **Homan M**, Hojsak I, Kolaček S. *Helicobacter pylori* in pediatric patients. *Helicobacter* 2012; **17** Suppl 1: 43-48 [PMID: 22958155 DOI: 10.1111/j.1523-5378.2012.00982.x]
- 31 **Marshall B**. *Helicobacter pylori*: 20 years on. *Clin Med* 2002; **2**: 147-152 [PMID: 11991099]
- 32 **Paterson WG**. Extraesophageal complications of gastroesophageal reflux disease. *Can J Gastroenterol* 1997; **11** Suppl B: 45B-50B [PMID: 9347178]
- 33 **Yemisen M**, Mete B, Kanbay A, Balkan II, Ozaras R. The Role of *Helicobacter pylori* in Upper Respiratory System Infections: Is it More Than Colonization? *Curr Infect Dis Rep* 2012; **14**: 128-136 [PMID: 22311663 DOI: 10.1007/s11908-012-0237-9]
- 34 **Kurtaran H**, Uyar ME, Kasapoglu B, Turkay C, Yilmaz T, Akcay A, Kanbay M. Role of *Helicobacter pylori* in pathogenesis of upper respiratory system diseases. *J Natl Med Assoc* 2008; **100**: 1224-1230 [PMID: 18942285]
- 35 **Blaser MJ**, Chen Y, Reibman J. Does *Helicobacter pylori* protect against asthma and allergy? *Gut* 2008; **57**: 561-567 [PMID: 18194986 DOI: 10.1136/gut.2007.133462]
- 36 **Chen Y**, Blaser MJ. Inverse associations of *Helicobacter pylori* with asthma and allergy. *Arch Intern Med* 2007; **167**: 821-827 [PMID: 17452546]
- 37 **Chen Y**, Blaser MJ. *Helicobacter pylori* colonization is inversely associated with childhood asthma. *J Infect Dis* 2008; **198**: 553-560 [PMID: 18598192 DOI: 10.1086/590158]
- 38 **Herbarth O**, Bauer M, Fritz GJ, Herbarth P, Rolle-Kampczyk U, Krumbiegel P, Richter M, Richter T. *Helicobacter pylori* colonisation and eczema. *J Epidemiol Community Health* 2007; **61**: 638-640 [PMID: 17568058]
- 39 **Taube C**, Müller A. The role of *Helicobacter pylori* infection in the development of allergic asthma. *Expert Rev Respir Med* 2012; **6**: 441-449 [PMID: 22971068 DOI: 10.1586/ers.12.40]
- 40 **Arnold IC**, Hitzler I, Müller A. The immunomodulatory properties of *Helicobacter pylori* confer protection against allergic and chronic inflammatory disorders. *Front Cell Infect Microbiol* 2012; **2**: 10 [PMID: 22919602 DOI: 10.3389/fcimb.2012.00010]
- 41 **Bousquet J**, Schünemann HJ, Samolinski B, Demoly P, Baeana-Cagnani CE, Bachert C, Bonini S, Boulet LP, Bousquet PJ, Brozek JL, Canonica GW, Casale TB, Cruz AA, Fokkens WJ, Fonseca JA, van Wijk RG, Grouse L, Haahtela T, Khaltaev N, Kuna P, Lockey RF, Lodrup Carlsen KC, Mullol J, Naclerio R, O'Hehir RE, Ohta K, Palkonen S, Papadopoulos NG, Passalacqua G, Pawankar R, Price D, Ryan D, Simons FE, Togias A, Williams D, Yorgancioglu A, Yusuf OM, Aberer W, Adachi M, Agache I, Ait-Khaled N, Akdis CA, Andrianarisoa A, Annesi-Maesano I, Ansotegui IJ, Baiardini I, Bateman ED, Bedbrook A, Beghé B, Beji M, Bel EH, Ben Kheder A, Bennoor KS, Bergmann KC, Berrissoul F, Bieber T, Bindeslev Jensen C, Blaiss MS, Boner AL, Bouchard J, Braidó F, Brightling CE, Bush A, Caballero F, Calderon MA, Calvo MA, Camargos PA, Caraballo LR, Carlsen KH, Carr W, Cepeda AM, Cesario A, Chavannes NH, Chen YZ, Chiriac AM, Chivato Pérez T, Chkhartishvili E, Ciprandi G, Costa DJ, Cox L, Custovic A, Dahl R, Darsow U, De Blay F, Deleau D, Denburg JA, Devillier P, Didi T, Dokic D, Dolen WK, Douagui H, Dubakien R, Durham SR, Dykewicz MS, El-Gamal Y, El-Meziane A, Emuzyte R, Fiocchi A, Fletcher M, Fukuda T, Gamkrelidze A, Gereda JE, González Diaz S, Gotua M, Guzmán MA, Hellings PW, Hellquist-Dahl B, Horak F, Hourihane JO, Howarth P, Humbert M, Ivancevich JC, Jackson C, Just J, Kalayci O, Kaliner MA, Kalyoncu AF, Keil T, Keith PK, Khayat G, Kim YY, Koffi N'goran B, Koppelman GH, Kowalski ML, Kull I, Kvedariene V, Larenas-Linnemann D, Le LT, Lemièrre C, Li J, Lieberman P, Lipworth B, Mahboub B, Makela MJ, Martin F, Marshall GD, Martinez FD, Masjedi MR, Maurer M, Mavale-Manuel S, Mazon A, Melen E, Meltzer EO, Mendez NH, Merk H, Mihaltan F, Mohammad Y, Morais-Almeida M, Muraro A, Nafti S, Namazova-Baranova L, Nekam K, Neou A, Niggemann B, Nizankowska-Mogilnicka E, Nyembue TD, Okamoto Y, Okubo K, Orru MP, Ouedraogo S, Ozdemir C, Panzner P, Pali-Schöll I, Park HS, Pigearias B, Pohl W, Popov TA, Postma DS, Potter P, Rabe KF, Ratomaharo J, Reitamo S, Ring J, Roberts R, Rogala B, Romano A, Roman Rodriguez M, Rosado-Pinto J, Rosenwasser L, Rottem M, Sanchez-Borges M, Scadding GK, Schmid-Grendelmeier P, Sheikh A, Sisul JC, Solé D, Sooronbaev T, Spicak V, Spranger O, Stein RT, Stollhoff SW, Sunyer J, Szczeklik A, Todo-Bom A, Toskala E, Tremblay Y, Valenta R, Valero AL, Valeyre D, Valiulis A, Valovirta E, Van Cauwenberge P, Vandenplas O, van Weel C, Vichyanond P, Viegi G, Wang DY, Wickman M, Wöhrl S, Wright J, Yawn BP, Yiallourous PK, Zar HJ, Zernotti ME, Zhong N, Zidarn M, Zuberbier T, Burney PG, Johnston SL, Warner JO; World Health Organization Collaborating Center for Asthma and Rhinitis. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. *J Allergy Clin Immunol* 2012; **130**: 1049-1062 [PMID: 23040884 DOI: 10.1016/j.jaci.2012.07.053]
- 42 **Ryan MW**. Asthma and rhinitis: comorbidities. *Otolaryngol Clin North Am* 2008; **41**: 283-295, vi [PMID: 18328368 DOI: 10.1016/j.otc.2007.11.005]
- 43 **Cellini L**, Allocati N, Dainelli B. Failure to detect *Helicobacter pylori* in nasal mucus in H pylori positive dyspeptic patients. *J Clin Pathol* 1995; **48**: 1072-1073 [PMID: 8543639]
- 44 **Imamura S**, Sugimoto M, Kanemasa K, Sumida Y, Okanoue T, Yoshikawa T, Yamaoka Y. Inverse association between *Helicobacter pylori* infection and allergic rhinitis in young Japanese. *J Gastroenterol Hepatol* 2010; **25**: 1244-1249 [PMID: 20594251 DOI: 10.1111/j.1440-1746.2010.06307.x]
- 45 **Cremonini F**, Gasbarrini A. Atopy, *Helicobacter pylori* and the hygiene hypothesis. *Eur J Gastroenterol Hepatol* 2003; **15**: 635-636 [PMID: 12840674]
- 46 **Lee YY**, Mahendra Raj S, Graham DY. *Helicobacter pylori* infection--a boon or a bane: lessons from studies in a low-prevalence population. *Helicobacter* 2013; **18**: 338-346 [PMID: 23607896 DOI: 10.1111/hel.12058]
- 47 **Raj SM**, Choo KE, Noorizan AM, Lee YY, Graham DY. Evidence against *Helicobacter pylori* Being Related to Childhood Asthma. *J Infect Dis* 2009; **199**: 914-915 [PMID: 19239342 DOI: 10.1086/597066]
- 48 **Bernstein JA**. Nonallergic rhinitis: therapeutic options. *Curr Opin Allergy Clin Immunol* 2013; **13**: 410-416 [PMID: 23756873 DOI: 10.1097/ACI.0b013e3283283630cd8]
- 49 **Hamilos DL**. Chronic rhinosinusitis: epidemiology and medical management. *J Allergy Clin Immunol* 2011; **128**: 693-707; quiz 708-709 [PMID: 21890184 DOI: 10.1016/j.jaci.2011.08.004]
- 50 **Dykewicz MS**, Hamilos DL. Rhinitis and sinusitis. *J Allergy Clin Immunol* 2010; **125**: S103-S115 [PMID: 20176255 DOI: 10.1016/j.jaci.2009.12.989]
- 51 **Fokkens WJ**, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, Cohen N, Cervin A, Douglas R, Gevaert P, Georgalas C, Goossens H, Harvey R, Hellings P, Hopkins C, Jones N, Joos G, Kalogjera L, Kern B, Kowalski M, Price D, Riechelmann H, Schlosser R, Senior B, Thomas M, Toskala E, Voegels R, Wang de Y, Wormald PJ. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. *Rhinol Suppl* 2012; **(23)**: 3 p preceding table of contents, 1-298 [PMID: 22764607]
- 52 **Ozyurt M**, Gungor A, Ergunay K, Cekin E, Erkul E, Haznedaroglu T. Real-time PCR detection of *Helicobacter pylori* and virulence-associated *cagA* in nasal polyps and laryngeal disorders. *Otolaryngol Head Neck Surg* 2009; **141**: 131-135 [PMID: 19559972 DOI: 10.1016/j.otohns.2009.04.005]
- 53 **Szczygielski K**, Jurkiewicz D, Rapiejko P. Detection of *Helicobacter pylori* in nasal polyps specimens using urease test GUT plus. *Pol Merkur Lekarski* 2005; **19**: 309-311 [PMID: 16358853]
- 54 **Kaviani M**, Khademi B, Mousavi SA, Azarpira N, Ashraf MJ. Determination of *Helicobacter pylori* in nasal polyposis

- with use of rapid urease test and ELISA. *Iran J Otorhinolaryngol* 2009; **20**: 189-193
- 55 **Cvorovic L**, Brajovic D, Strbac M, Milutinovic Z, Cvorovic V. Detection of *Helicobacter pylori* in nasal polyps: preliminary report. *J Otolaryngol Head Neck Surg* 2008; **37**: 192-195 [PMID: 19128611]
  - 56 **Dinis PB**, Martins ML, Subtil J. Does *Helicobacter pylori* play a role in upper respiratory tract inflammation? A case report. *Ear Nose Throat J* 2005; **84**: 238-240 [PMID: 15929324]
  - 57 **Včeva A**, Danić D, Včev A, Birtić D, Mihalj H, Zubčić Z, Kotromanović Z, Danić Hadžibegović A. The significance of *Helicobacter pylori* in patients with nasal polyposis. *Med Glas (Zenica)* 2012; **9**: 281-286 [PMID: 22926364]
  - 58 **Burduk PK**, Kaczmarek A, Budzynska A, Kazmierczak W, Gospodarek E. Detection of *Helicobacter pylori* and *cagA* gene in nasal polyps and benign laryngeal diseases. *Arch Med Res* 2011; **42**: 686-689 [PMID: 22222490 DOI: 10.1016/j.arcmed.2011.12.005]
  - 59 **Morinaka S**, Ichimiya M, Nakamura H. Detection of *Helicobacter pylori* in nasal and maxillary sinus specimens from patients with chronic sinusitis. *Laryngoscope* 2003; **113**: 1557-1563 [PMID: 12972933]
  - 60 **Ozdek A**, Cirak MY, Samim E, Bayiz U, Safak MA, Turet S. A possible role of *Helicobacter pylori* in chronic rhinosinusitis: a preliminary report. *Laryngoscope* 2003; **113**: 679-682 [PMID: 12671428]
  - 61 **Koc C**, Arıkan OK, Atasoy P, Aksoy A. Prevalence of *Helicobacter pylori* in patients with nasal polyps: a preliminary report. *Laryngoscope* 2004; **114**: 1941-1944 [PMID: 15510018]
  - 62 **Kim HY**, Dhong HJ, Chung SK, Chung KW, Chung YJ, Jang KT. Intranasal *Helicobacter pylori* colonization does not correlate with the severity of chronic rhinosinusitis. *Otolaryngol Head Neck Surg* 2007; **136**: 390-395 [PMID: 17321865]
  - 63 **Jelavic B**, Grgić M, Cupić H, Kordić M, Vasilj M, Baudoin T. Prognostic value of *Helicobacter pylori* sinonasal colonization for efficacy of endoscopic sinus surgery. *Eur Arch Otorhinolaryngol* 2012; **269**: 2197-2202 [PMID: 22237763 DOI: 10.1007/s00405-012-1923-9]
  - 64 **Ozcan C**, Polat A, Otağ F, Görür K. Does *Helicobacter pylori* play a role in etiology of nasal polyposis? *Auris Nasus Larynx* 2009; **36**: 427-430 [PMID: 19010623 DOI: 10.1016/j.anl.2008.09.007]
  - 65 **DiBaise JK**, Huerter JV, Quigley EM. Sinusitis and gastroesophageal reflux disease. *Ann Intern Med* 1998; **129**: 1078 [PMID: 9867773]
  - 66 **DiBaise JK**, Olusola BF, Huerter JV, Quigley EM. Role of GERD in chronic resistant sinusitis: a prospective, open label, pilot trial. *Am J Gastroenterol* 2002; **97**: 843-850 [PMID: 12003417]
  - 67 **Dibaise JK**, Sharma VK. Does gastroesophageal reflux contribute to the development of chronic sinusitis? A review of the evidence. *Dis Esophagus* 2006; **19**: 419-424 [PMID: 17069583]
  - 68 **Katle EJ**, Hatlebakk JG, Steinsvåg S. Gastroesophageal reflux and rhinosinusitis. *Curr Allergy Asthma Rep* 2013; **13**: 218-223 [PMID: 23371037 DOI: 10.1007/s11882-013-0340-5]
  - 69 **Ulualp SO**, Toohill RJ, Hoffmann R, Shaker R. Possible relationship of gastroesophagopharyngeal acid reflux with pathogenesis of chronic sinusitis. *Am J Rhinol* 1999; **13**: 197-202 [PMID: 10392238]
  - 70 **Bothwell MR**, Parsons DS, Talbot A, Barbero GJ, Wilder B. Outcome of reflux therapy on pediatric chronic sinusitis. *Otolaryngol Head Neck Surg* 1999; **121**: 255-262 [PMID: 10471867]
  - 71 **Dinis PB**, Subtil J. *Helicobacter pylori* and laryngopharyngeal reflux in chronic rhinosinusitis. *Otolaryngol Head Neck Surg* 2006; **134**: 67-72 [PMID: 16399183]
  - 72 **Nemati S**, Mojtahedi A, Naghavi SE, Banan R, Zia F. Investigating *Helicobacter pylori* in nasal polyposis using polymerase chain reaction, urease test and culture. *Eur Arch Otorhinolaryngol* 2012; **269**: 1457-1461 [PMID: 22116383 DOI: 10.1007/s00405-011-1848-8]
  - 73 **Unver S**, Kubilay U, Sezen OS, Coskuner T. Investigation of *Helicobacter pylori* colonization in adenotonsillectomy specimens by means of the CLO test. *Laryngoscope* 2001; **111**: 2183-2186 [PMID: 11802022]
  - 74 **Khademi B**, Imanieh MH, Gandomi B, Yeganeh F, Niknejad N. Investigation of *H. pylori* colonization in adenotonsillectomy specimens by means of rapid urease (CLO) test. *Iran J Med Sci* 2005; **30**: 138-140
  - 75 **Farhadi M**, Noorbakhsh S, Tabatabaei A. Searching the *H. pylori*; serology & amp; PCR in children with adenoid hypertrophy and rhino sinusitis: a cross sectional study, Tehran, Iran. *Med J Islam Repub Iran* 2013; **27**: 77-82 [PMID: 23741169]
  - 76 **Eyigor M**, Eyigor H, Gultekin B, Aydin N. Detection of *Helicobacter pylori* in adenotonsillar tissue specimens by rapid urease test and polymerase chain reaction. *Eur Arch Otorhinolaryngol* 2009; **266**: 1611-1613 [PMID: 19130070 DOI: 10.1007/s00405-008-0903-6]
  - 77 **Cirak MY**, Ozdek A, Yilmaz D, Bayiz U, Samim E, Turet S. Detection of *Helicobacter pylori* and its *CagA* gene in tonsil and adenoid tissues by PCR. *Arch Otolaryngol Head Neck Surg* 2003; **129**: 1225-1229 [PMID: 14623755]
  - 78 **Adams BL**, Bates TC, Oliver JD. Survival of *Helicobacter pylori* in a natural freshwater environment. *Appl Environ Microbiol* 2003; **69**: 7462-7466 [PMID: 14660399]
  - 79 **Piqueres P**, Moreno Y, Alonso JL, Ferrús MA. A combination of direct viable count and fluorescent in situ hybridization for estimating *Helicobacter pylori* cell viability. *Res Microbiol* 2006; **157**: 345-349 [PMID: 16380234]
  - 80 **Abdel-Monem MH**, Magdy EA, Nour YA, Harfoush RA, Ibreak A. Detection of *Helicobacter pylori* in adenotonsillar tissue of children with chronic adenotonsillitis using rapid urease test, PCR and blood serology: a prospective study. *Int J Pediatr Otorhinolaryngol* 2011; **75**: 568-572 [PMID: 21324534 DOI: 10.1016/j.ijporl.2011.01.021]
  - 81 **Bulut Y**, Agacayak A, Karlıdag T, Toraman ZA, Yilmaz M. Association of *cagA+* *Helicobacter pylori* with adenotonsillar hypertrophy. *Tohoku J Exp Med* 2006; **209**: 229-233 [PMID: 16778369]
  - 82 **Vilarinho S**, Guimarães NM, Ferreira RM, Gomes B, Wen X, Vieira MJ, Carneiro F, Godinho T, Figueiredo C. *Helicobacter pylori* colonization of the adenotonsillar tissue: fact or fiction? *Int J Pediatr Otorhinolaryngol* 2010; **74**: 807-811 [PMID: 20452684 DOI: 10.1016/j.ijporl.2010.04.007]
  - 83 **Hussey DJ**, Woods CM, Harris PK, Thomas AC, Ooi EH, Carney AS. Absence of *Helicobacter pylori* in pediatric adenoid hyperplasia. *Arch Otolaryngol Head Neck Surg* 2011; **137**: 998-1004 [PMID: 22006777 DOI: 10.1001/archoto.2011.136]
  - 84 **Vayisoglu Y**, Ozcan C, Polat A, Delialioğlu N, Gorur K. Does *Helicobacter pylori* play a role in the development of chronic adenotonsillitis? *Int J Pediatr Otorhinolaryngol* 2008; **72**: 1497-1501 [PMID: 18691771 DOI: 10.1016/j.ijporl.2008.06.018]
  - 85 **Bitar MA**, Soweid A, Mahfouz R, Zaatarı G, Fuleihan N. Is *Helicobacter pylori* really present in the adenoids of children? *Eur Arch Otorhinolaryngol* 2005; **262**: 987-992 [PMID: 15924276]
  - 86 **Bitar M**, Mahfouz R, Soweid A, Racoubian E, Ghasham M, Zaatarı G, Fuleihan N. Does *Helicobacter pylori* colonize the nasopharynx of children and contribute to their middle ear disease? *Acta Otolaryngol* 2006; **126**: 154-159 [PMID: 16428192]
  - 87 **Pitkäranta A**, Kolho KL, Rautelin H. *Helicobacter pylori* in children who are prone to upper respiratory tract infections. *Arch Otolaryngol Head Neck Surg* 2005; **131**: 256-258 [PMID: 15781769]
  - 88 **Toros SZ**, Toros AB, Kaya KS, Deveci I, Özel L, Naiboğlu B, Habaşoğlu T, Egeli E. A study to detect *Helicobacter pylori* in adenotonsillar tissue. *Ear Nose Throat J* 2011; **90**: E32 [PMID: 21324534 DOI: 10.1016/j.ijporl.2011.01.021]

- 21500158]
- 89 **Ozcan C**, Vayisoglu Y, Otag F, Polat A, Görür K, Ismi O. Does *Helicobacter pylori* have a role in the development of chronic otitis media with effusion? A preliminary study. *J Otolaryngol Head Neck Surg* 2009; **38**: 526-531 [PMID: 19769821]
  - 90 **Fancy T**, Mathers PH, Ramadan HH. Otitis media with effusion: a possible role for *Helicobacter pylori*? *Otolaryngol Head Neck Surg* 2009; **140**: 256-258 [PMID: 19201299 DOI: 10.1016/j.otohns.2008.11.023]
  - 91 **Yilmaz T**, Ceylan M, Akyön Y, Özçakır O, Gürsel B. *Helicobacter pylori*: a possible association with otitis media with effusion. *Otolaryngol Head Neck Surg* 2006; **134**: 772-777 [PMID: 16647533]
  - 92 **Yilmaz MD**, Aktepe O, Cetinkol Y, Altuntaş A. Does *Helicobacter pylori* have role in development of otitis media with effusion? *Int J Pediatr Otorhinolaryngol* 2005; **69**: 745-749 [PMID: 15885326]
  - 93 **Agirdir BV**, Bozova S, Derin AT, Turhan M. Chronic otitis media with effusion and *Helicobacter pylori*. *Int J Pediatr Otorhinolaryngol* 2006; **70**: 829-834 [PMID: 16309749]
  - 94 **Morinaka S**, Tominaga M, Nakamura H. Detection of *Helicobacter pylori* in the middle ear fluid of patients with otitis media with effusion. *Otolaryngol Head Neck Surg* 2005; **133**: 791-794 [PMID: 16274811]
  - 95 **Karlıdag T**, Bulut Y, Keles E, Kaygusuz I, Yalcin S, Ozdarendeli A, Dabak H. Detection of *Helicobacter pylori* in children with otitis media with effusion: a preliminary report. *Laryngoscope* 2005; **115**: 1262-1265 [PMID: 15995518]
  - 96 **Park CW**, Chung JH, Min HJ, Kim KR, Tae K, Cho SH, Lee SH. *Helicobacter pylori* in middle ear of children with otitis media with effusion. *Chin Med J (Engl)* 2011; **124**: 4275-4278 [PMID: 22340399]
  - 97 **Bai X**, Wang D, Fan Z, Han Y, Xu L, Zhang G, Lu S, Liu W, Li J, Wang H. *Helicobacter pylori* may cause otitis media with effusion: a pilot study. *B-ENT* 2012; **8**: 261-264 [PMID: 23409554]
  - 98 **Sudhoff H**, Rajagopal S, Baguley DM, Ebmeyer J, Schmelzer A, Schreiber S, Moffat DA. A critical evaluation of the evidence on a causal relationship between *Helicobacter pylori* and otitis media with effusion. *J Laryngol Otol* 2008; **122**: 905-911 [PMID: 18036278]
  - 99 **Aycicek A**, Çetinkaya Z, Kıyıcı H, Bukulmez A, Yucedag F. Can *Helicobacter pylori* cause inflammation in the middle ear? *Int J Pediatr Otorhinolaryngol* 2012; **76**: 1087-1090 [PMID: 22552023 DOI: 10.1016/j.ijporl.2012.04.005]
  - 100 **Kariya S**, Okano M, Fukushima K, Nomiya S, Kataoka Y, Nomiya R, Akagi H, Nishizaki K. Expression of inflammatory mediators in the otitis media induced by *Helicobacter pylori* antigen in mice. *Clin Exp Immunol* 2008; **154**: 134-140 [PMID: 18727622 DOI: 10.1111/j.1365-2249.2008.03740.x]
  - 101 **Kutluhan A**, Yurttaş V, Akarca US, Aydın A, Tuncer I, Uğraş S. Possible role of *Helicobacter pylori* in the etiopathogenesis of chronic otitis media. *Otol Neurotol* 2005; **26**: 1125-1127 [PMID: 16272928]
  - 102 **Dagli M**, Eryilmaz A, Uzun A, Kayhan B, Karabulut H. Investigation of *Helicobacter pylori* in the middle ear of the patients with chronic otitis media by CLO test and 14C urea breath test. *Otol Neurotol* 2006; **27**: 871-873 [PMID: 16865050]
  - 103 **Lieberthal AS**, Carroll AE, Chonmaitree T, Ganiats TG, Hoberman A, Jackson MA, Joffe MD, Miller DT, Rosenfeld RM, Sevilla XD, Schwartz RH, Thomas PA, Tunkel DE. The diagnosis and management of acute otitis media. *Pediatrics* 2013; **131**: e964-e999 [PMID: 23439909 DOI: 10.1542/peds.2012-3488]
  - 104 **Majmudar P**, Shah SM, Dhunjibhoy KR, Desai HG. Isolation of *Helicobacter pylori* from dental plaques in healthy volunteers. *Indian J Gastroenterol* 1990; **9**: 271-272 [PMID: 2258210]
  - 105 **Song Q**, Lange T, Spahr A, Adler G, Bode G. Characteristic distribution pattern of *Helicobacter pylori* in dental plaque and saliva detected with nested PCR. *J Med Microbiol* 2000; **49**: 349-353 [PMID: 10755629]
  - 106 **Hirsch C**, Tegtmeyer N, Rohde M, Rowland M, Oyarzabal OA, Backert S. Live *Helicobacter pylori* in the root canal of endodontic-infected deciduous teeth. *J Gastroenterol* 2012; **47**: 936-940 [PMID: 22722905 DOI: 10.1007/s00535-012-0618-8]
  - 107 **Yee KC**, Wei MH, Yee HC, Everett KD, Yee HP, Hazeki-Talor N. A screening trial of *Helicobacter pylori*-specific antigen tests in saliva to identify an oral infection. *Digestion* 2013; **87**: 163-169 [PMID: 23615458 DOI: 10.1159/000350432]
  - 108 **Ferguson DA**, Li C, Patel NR, Mayberry WR, Chi DS, Thomas E. Isolation of *Helicobacter pylori* from saliva. *J Clin Microbiol* 1993; **31**: 2802-2804 [PMID: 8253990]
  - 109 **Li C**, Musich PR, Ha T, Ferguson DA, Patel NR, Chi DS, Thomas E. High prevalence of *Helicobacter pylori* in saliva demonstrated by a novel PCR assay. *J Clin Pathol* 1995; **48**: 662-666 [PMID: 7560176]
  - 110 **Bernander S**, Dalén J, Gästrin B, Hedenborg L, Lamke LO, Ohn R. Absence of *Helicobacter pylori* in dental plaques in *Helicobacter pylori* positive dyspeptic patients. *Eur J Clin Microbiol Infect Dis* 1993; **12**: 282-285 [PMID: 8513816]
  - 111 **Wahlfors J**, Meurman JH, Toskala J, Korhonen A, Alakuijala P, Janatuinen E, Kärkkäinen UM, Nuutinen P, Jänne J. Development of a rapid PCR method for identification of *Helicobacter pylori* in dental plaque and gastric biopsy specimens. *Eur J Clin Microbiol Infect Dis* 1995; **14**: 780-786 [PMID: 8536726]
  - 112 **Bickley J**, Owen RJ, Fraser AG, Pounder RE. Evaluation of the polymerase chain reaction for detecting the urease C gene of *Helicobacter pylori* in gastric biopsy samples and dental plaque. *J Med Microbiol* 1993; **39**: 338-344 [PMID: 8246250]
  - 113 **Luman W**, Alkout AM, Blackwell CC, Weir DM, Plamer KR. *Helicobacter pylori* in the mouth--negative isolation from dental plaque and saliva. *Eur J Gastroenterol Hepatol* 1996; **8**: 11-14 [PMID: 8900903]
  - 114 **Al-Ahmad A**, Kürschner A, Weckesser S, Wittmer A, Rauberger H, Jakob T, Hellwig E, Kist M, Waidner B. Is *Helicobacter pylori* resident or transient in the human oral cavity? *J Med Microbiol* 2012; **61**: 1146-1152 [PMID: 22499779 DOI: 10.1099/jmm.0.043893-0]
  - 115 **D'Alessandro A**, Seri S. Comparison of three different methods for evaluation of *Helicobacter pylori* (H.P.) in human dental plaque. *Boll Soc Ital Biol Sper* 1992; **68**: 769-773 [PMID: 1307023]
  - 116 **Cellini L**, Allocati N, Piattelli A, Petrelli I, Fanci P, Dainelli B. Microbiological evidence of *Helicobacter pylori* from dental plaque in dyspeptic patients. *New Microbiol* 1995; **18**: 187-192 [PMID: 7603346]
  - 117 **Riggio MP**, Lennon A. Identification by PCR of *Helicobacter pylori* in subgingival plaque of adult periodontitis patients. *J Med Microbiol* 1999; **48**: 317-322 [PMID: 10334600 DOI: 10.1099/00222615-48-3-317]
  - 118 **Chaudhry S**, Idrees M, Izhar M, Butt AK, Khan AA. Simultaneous amplification of two bacterial genes: more reliable method of *Helicobacter pylori* detection in microbial rich dental plaque samples. *Curr Microbiol* 2011; **62**: 78-83 [PMID: 20512648 DOI: 10.1007/s00284-010-9662-x]
  - 119 **Butt AK**, Khan AA, Bedi R. *Helicobacter pylori* in dental plaque of Pakistanis. *J Int Acad Periodontol* 1999; **1**: 78-82 [PMID: 10833287]
  - 120 **Tsami A**, Petropoulou P, Kafritsa Y, Mentis YA, Romagiannikou E. The presence of *Helicobacter pylori* in dental plaque of children and their parents: is it related to their periodontal status and oral hygiene? *Eur J Paediatr Dent* 2011; **12**: 225-230 [PMID: 22185245]
  - 121 **Sudhakar U**, Anusuya CN, Ramakrishnan T, Vijayalakshmi R. Isolation of *Helicobacter pylori* from dental plaque: A microbiological study. *J Indian Soc Periodontol* 2008; **12**: 67-72 [PMID: 20142948 DOI: 10.4103/0972-124X.44098]
  - 122 **Liu Y**, Yue H, Li A, Wang J, Jiang B, Zhang Y, Bai Y. An



- epidemiologic study on the correlation between oral *Helicobacter pylori* and gastric *H. pylori*. *Curr Microbiol* 2009; **58**: 449-453 [PMID: 19139956 DOI: 10.1007/s00284-008-9341-3]
- 123 **Silva DG**, Tinoco EM, Rocha GA, Rocha AM, Guerra JB, Saraiva IE, Queiroz DM. *Helicobacter pylori* transiently in the mouth may participate in the transmission of infection. *Mem Inst Oswaldo Cruz* 2010; **105**: 657-660 [PMID: 20835612]
  - 124 **Dowsett SA**, Archila L, Segreto VA, Gonzalez CR, Silva A, Vastola KA, Bartizek RD, Kowolik MJ. *Helicobacter pylori* infection in indigenous families of Central America: serostatus and oral and fingernail carriage. *J Clin Microbiol* 1999; **37**: 2456-2460 [PMID: 10405384]
  - 125 **Allaker RP**, Young KA, Hardie JM, Domizio P, Meadows NJ. Prevalence of *Helicobacter pylori* at oral and gastrointestinal sites in children: evidence for possible oral-to-oral transmission. *J Med Microbiol* 2002; **51**: 312-317 [PMID: 11926736]
  - 126 **Assumpção MB**, Martins LC, Melo Barbosa HP, Barile KA, de Almeida SS, Assumpção PP, Corvelo TC. *Helicobacter pylori* in dental plaque and stomach of patients from Northern Brazil. *World J Gastroenterol* 2010; **16**: 3033-3039 [PMID: 20572307 DOI: 10.3748/wjg.v16.i24.3033]
  - 127 **Gao J**, Li Y, Wang Q, Qi C, Zhu S. Correlation between distribution of *Helicobacter pylori* in oral cavity and chronic stomach conditions. *J Huazhong Univ Sci Technolog Med Sci* 2011; **31**: 409-412 [PMID: 21671188 DOI: 10.1007/s11596-011-0391-6]
  - 128 **Namavar F**, Roosendaal R, Kuipers EJ, de Groot P, van der Bijl MW, Peña AS, de Graaff J. Presence of *Helicobacter pylori* in the oral cavity, oesophagus, stomach and faeces of patients with gastritis. *Eur J Clin Microbiol Infect Dis* 1995; **14**: 234-237 [PMID: 7614967]
  - 129 **Momtaz H**, Souod N, Dabiri H, Sarshar M. Study of *Helicobacter pylori* genotype status in saliva, dental plaques, stool and gastric biopsy samples. *World J Gastroenterol* 2012; **18**: 2105-2111 [PMID: 22563199 DOI: 10.3748/wjg.v18.i17.2105]
  - 130 **Sahin FI**, Tinaz AC, Simsek IS, Menevşe S, Görgül A. Detection of *Helicobacter pylori* in dental plaque and gastric biopsy samples of Turkish patients by PCR-RFLP. *Acta Gastroenterol Belg* 2001; **64**: 150-152 [PMID: 11475123]
  - 131 **Doré-Davin C**, Heitz M, Yang H, Herranz M, Blum AL, Corthésy-Theulaz I. *Helicobacter pylori* in the oral cavity reflects handling of contaminants but not gastric infection. *Digestion* 1999; **60**: 196-202 [PMID: 10343132]
  - 132 **Cheng LH**, Webberley M, Evans M, Hanson N, Brown R. *Helicobacter pylori* in dental plaque and gastric mucosa. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1996; **81**: 421-423 [PMID: 8705587]
  - 133 **Silva Rossi-Aguiar VP**, Navarro-Rodriguez T, Mattar R, Siqueira de Melo Peres MP, Correa Barbuti R, Silva FM, Carrilho FJ, Eisig JN. Oral cavity is not a reservoir for *Helicobacter pylori* in infected patients with functional dyspepsia. *Oral Microbiol Immunol* 2009; **24**: 255-259 [PMID: 19416457 DOI: 10.1111/j.1399-302X.2008.00491.x]
  - 134 **Bürgers R**, Schneider-Brachert W, Reischl U, Behr A, Hiller KA, Lehn N, Schmalz G, Ruhl S. *Helicobacter pylori* in human oral cavity and stomach. *Eur J Oral Sci* 2008; **116**: 297-304 [PMID: 18705796 DOI: 10.1111/j.1600-0722.2008.00543.x]
  - 135 **Cześnikiewicz-Guzik M**, Karczewska E, Bielański W, Guzik TJ, Kapera P, Targosz A, Konturek SJ, Loster B. Association of the presence of *Helicobacter pylori* in the oral cavity and in the stomach. *J Physiol Pharmacol* 2004; **55** Suppl 2: 105-115 [PMID: 15608365]
  - 136 **Cammarota G**, Tursi A, Montalto M, Papa A, Veneto G, Bernardi S, Boari A, Colizzi V, Fedeli G, Gasbarrini G. Role of dental plaque in the transmission of *Helicobacter pylori* infection. *J Clin Gastroenterol* 1996; **22**: 174-177 [PMID: 8724252]
  - 137 **Loster BW**, Majewski SW, Cześnikiewicz-Guzik M, Bielański W, Pierzchalski P, Konturek SJ. The relationship between the presence of *Helicobacter pylori* in the oral cavity and gastric in the stomach. *J Physiol Pharmacol* 2006; **57** Suppl 3: 91-100 [PMID: 17033108]
  - 138 **Oshowo A**, Tunio M, Gillam D, Botha AJ, Holton J, Boulos P, Hobsley M. Oral colonization is unlikely to play an important role in *Helicobacter pylori* infection. *Br J Surg* 1998; **85**: 850-852 [PMID: 9667722]
  - 139 **Chaudhry S**, Iqbal HA, Khan AA, Izhar M, Butt AK, Akhter MW, Izhar F, Mirza KM. *Helicobacter pylori* in dental plaque and gastric mucosa: correlation revisited. *J Pak Med Assoc* 2008; **58**: 331-334 [PMID: 18988394]
  - 140 **Berroteran A**, Perrone M, Correnti M, Cavazza ME, Tombazzi C, Goncalvez R, Lecuna V. Detection of *Helicobacter pylori* DNA in the oral cavity and gastroduodenal system of a Venezuelan population. *J Med Microbiol* 2002; **51**: 764-770 [PMID: 12358067]
  - 141 **Zou QH**, Li RQ. *Helicobacter pylori* in the oral cavity and gastric mucosa: a meta-analysis. *J Oral Pathol Med* 2011; **40**: 317-324 [PMID: 21294774 DOI: 10.1111/j.1600-0714.2011.01006.x]
  - 142 **Cellini L**, Grande R, Artese L, Marzio L. Detection of *Helicobacter pylori* in saliva and esophagus. *New Microbiol* 2010; **33**: 351-357 [PMID: 21213594]
  - 143 **Fernández-Tilapa G**, Axinecuilteco-Hilera J, Giono-Cerezo S, Martínez-Carrillo DN, Illades-Aguar B, Román-Román A. *vacA* genotypes in oral cavity and *Helicobacter pylori* seropositivity among adults without dyspepsia. *Med Oral Patol Oral Cir Bucal* 2011; **16**: e175-e180 [PMID: 20711119]
  - 144 **Eskandari A**, Mahmoudpour A, Abolfazli N, Lafzi A. Detection of *Helicobacter pylori* using PCR in dental plaque of patients with and without gastritis. *Med Oral Patol Oral Cir Bucal* 2010; **15**: e28-e31 [PMID: 19767693]
  - 145 **Karczewska E**, Konturek JE, Konturek PC, Cześnikiewicz M, Sito E, Bielański W, Kwiecień N, Obtulowicz W, Ziemiński W, Majka J, Hahn EG, Konturek SJ. Oral cavity as a potential source of gastric reinfection by *Helicobacter pylori*. *Dig Dis Sci* 2002; **47**: 978-986 [PMID: 12018924]
  - 146 **Madinier IM**, Fosse TM, Monteil RA. Oral carriage of *Helicobacter pylori*: a review. *J Periodontol* 1997; **68**: 2-6 [PMID: 9029444]
  - 147 **Nguyen AM**, Engstrand L, Genta RM, Graham DY, el-Zaatari FA. Detection of *Helicobacter pylori* in dental plaque by reverse transcription-polymerase chain reaction. *J Clin Microbiol* 1993; **31**: 783-787 [PMID: 8463387]
  - 148 **Silva DG**, Stevens RH, Macedo JM, Albano RM, Falabella ME, Veerman EC, Tinoco EM. Detection of cytotoxin genotypes of *Helicobacter pylori* in stomach, saliva and dental plaque. *Arch Oral Biol* 2009; **54**: 684-688 [PMID: 19442963 DOI: 10.1016/j.archoralbio.2009.04.006]
  - 149 **Rasmussen LT**, Labio RW, Gatti LL, Silva LC, Queiroz VF, Smith Mde A, Payão SL. *Helicobacter pylori* detection in gastric biopsies, saliva and dental plaque of Brazilian dyspeptic patients. *Mem Inst Oswaldo Cruz* 2010; **105**: 326-330 [PMID: 20512249]
  - 150 **Oshowo A**, Gillam D, Botha A, Tunio M, Holton J, Boulos P, Hobsley M. *Helicobacter pylori*: the mouth, stomach, and gut axis. *Ann Periodontol* 1998; **3**: 276-280 [PMID: 9722711]
  - 151 **Al Asqah M**, Al Hamoudi N, Anil S, Al Jebreen A, Al-Hamoudi WK. Is the presence of *Helicobacter pylori* in dental plaque of patients with chronic periodontitis a risk factor for gastric infection? *Can J Gastroenterol* 2009; **23**: 177-179 [PMID: 19319381]
  - 152 **Navabi N**, Aramon M, Mirzazadeh A. Does the presence of the *Helicobacter pylori* in the dental plaque associate with its gastric infection? A meta-analysis and systematic review. *Dent Res J (Isfahan)* 2011; **8**: 178-182 [PMID: 22135688 DOI: 10.4103/1735-3327.86033]
  - 153 **Kilmartin CM**. Dental implications of *Helicobacter pylori*. *J Can Dent Assoc* 2002; **68**: 489-493 [PMID: 12323105]
  - 154 **Pavelić J**, Gall-Troselj K, Jurak I, Mravak-Stipetić M. *Helicobacter pylori* in oral aphthous ulcers. *J Oral Pathol Med* 2000; **29**: 523-525 [PMID: 11048970]
  - 155 **Taş DA**, Yakar T, Sakalli H, Serin E. Impact of *Helicobacter*

- pylori* on the clinical course of recurrent aphthous stomatitis. *J Oral Pathol Med* 2013; **42**: 89-94 [PMID: 22827585 DOI: 10.1111/j.1600-0714.2012.01197.x]
- 156 **Karaca S**, Seyhan M, Senol M, Harputluoglu MM, Ozcan A. The effect of gastric *Helicobacter pylori* eradication on recurrent aphthous stomatitis. *Int J Dermatol* 2008; **47**: 615-617 [PMID: 18477159 DOI: 10.1111/j.1365-4632.2008.03667.x]
  - 157 **Birek C**, Grandhi R, McNeill K, Singer D, Ficarra G, Bowden G. Detection of *Helicobacter pylori* in oral aphthous ulcers. *J Oral Pathol Med* 1999; **28**: 197-203 [PMID: 10226941]
  - 158 **Albanidou-Farmaki E**, Giannoulis L, Markopoulos A, Fotiades S, Aggouridaki X, Farmakis K, Papanayotou P. Outcome following treatment for *Helicobacter pylori* in patients with recurrent aphthous stomatitis. *Oral Dis* 2005; **11**: 22-26 [PMID: 15641963]
  - 159 **Iamaroon A**, Chaimano S, Linpisarn S, Pongsiriwet S, Phornphutkul K. Detection of *Helicobacter pylori* in recurrent aphthous ulceration by nested PCR. *J Oral Sci* 2003; **45**: 107-110 [PMID: 12930134]
  - 160 **Fritscher AM**, Cherubini K, Chies J, Dias AC. Association between *Helicobacter pylori* and recurrent aphthous stomatitis in children and adolescents. *J Oral Pathol Med* 2004; **33**: 129-132 [PMID: 15128053]
  - 161 **Porter SR**, Barker GR, Scully C, Macfarlane G, Bain L. Serum IgG antibodies to *Helicobacter pylori* in patients with recurrent aphthous stomatitis and other oral disorders. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1997; **83**: 325-328 [PMID: 9084193]
  - 162 **Chapman MS**, Cimis RJ, Baughman RD. Lack of association between aphthous ulcers and *Helicobacter pylori*. *Arch Dermatol* 1998; **134**: 1634-1635 [PMID: 9875209]
  - 163 **Shimoyama T**, Horie N, Kato T, Kaneko T, Komiyama K. *Helicobacter pylori* in oral ulcerations. *J Oral Sci* 2000; **42**: 225-229 [PMID: 11269381]
  - 164 **Riggio MP**, Lennon A, Wray D. Detection of *Helicobacter pylori* DNA in recurrent aphthous stomatitis tissue by PCR. *J Oral Pathol Med* 2000; **29**: 507-513 [PMID: 11048967]
  - 165 **Maleki Z**, Sayyari AA, Alavi K, Sayyari L, Baharvand M. A study of the relationship between *Helicobacter pylori* and recurrent aphthous stomatitis using a urea breath test. *J Contemp Dent Pract* 2009; **10**: 9-16 [PMID: 19142251]
  - 166 **Mansour-Ghanaei F**, Asmar M, Bagherzadeh AH, Ekbataninezhad S. *Helicobacter pylori* infection in oral lesions of patients with recurrent aphthous stomatitis. *Med Sci Monit* 2005; **11**: CR576-CR579 [PMID: 16319788]
  - 167 **Victória JM**, Kalapothakis E, Silva Jde F, Gomez RS. *Helicobacter pylori* DNA in recurrent aphthous stomatitis. *J Oral Pathol Med* 2003; **32**: 219-223 [PMID: 12653861]
  - 168 **Afghani P**, Khazaei S, Kazemi S, Savabi O, Keshteli AH, Adibi P. The role of *Helicobacter pylori* in the development of recurrent aphthous stomatitis: SEPAHAN systematic review no. 9. *Dent Res J (Isfahan)* 2011; **8**: S2-S8 [PMID: 23372591]
  - 169 **Silva DG**, Stevens RH, Macedo JM, Albano RM, Falabella ME, Fischer RG, Veerman EC, Tinoco EM. Presence of *Helicobacter pylori* in supragingival dental plaque of individuals with periodontal disease and upper gastric diseases. *Arch Oral Biol* 2010; **55**: 896-901 [PMID: 20863482 DOI: 10.1016/j.archoralbio.2010.06.018]
  - 170 **Hardo PG**, Tugnait A, Hassan F, Lynch DA, West AP, Mapstone NP, Quirke P, Chalmers DM, Kowolik MJ, Axon AT. *Helicobacter pylori* infection and dental care. *Gut* 1995; **37**: 44-46 [PMID: 7672679]
  - 171 **Rajendran R**, Rajeev R, Anil S, Alasqah M, Rabi AG. *Helicobacter pylori* coinfection is a confounder, modulating mucosal inflammation in oral submucous fibrosis. *Indian J Dent Res* 2009; **20**: 206-211 [PMID: 19553724 DOI: 10.4103/0970-9290.52898]
  - 172 **Dye BA**, Kruszon-Moran D, McQuillan G. The relationship between periodontal disease attributes and *Helicobacter pylori* infection among adults in the United States. *Am J Public Health* 2002; **92**: 1809-1815 [PMID: 12406813]
  - 173 **Bago I**, Bago J, Plečko V, Aurer A, Majstorović K, Budimir A. The effectiveness of systemic eradication therapy against oral *Helicobacter pylori*. *J Oral Pathol Med* 2011; **40**: 428-432 [PMID: 21198868 DOI: 10.1111/j.1600-0714.2010.00989.x]
  - 174 **Gall-Troselj K**, Mravak-Stipetić M, Jurak I, Ragland WL, Pavelić J. *Helicobacter pylori* colonization of tongue mucosa-increased incidence in atrophic glossitis and burning mouth syndrome (BMS). *J Oral Pathol Med* 2001; **30**: 560-563 [PMID: 11555160]
  - 175 **Adler I**, Denninghoff VC, Alvarez MI, Avagnina A, Yoshida R, Elsner B. *Helicobacter pylori* associated with glossitis and halitosis. *Helicobacter* 2005; **10**: 312-317 [PMID: 16104947]
  - 176 **Tangerman A**, Winkel EG, de Laat L, van Oijen AH, de Boer WA. Halitosis and *Helicobacter pylori* infection. *J Breath Res* 2012; **6**: 017102 [PMID: 22368251 DOI: 10.1088/1752-7155/6/1/017102]
  - 177 **Suzuki N**, Yoneda M, Naito T, Iwamoto T, Masuo Y, Yamada K, Hisama K, Okada I, Hirofujii T. Detection of *Helicobacter pylori* DNA in the saliva of patients complaining of halitosis. *J Med Microbiol* 2008; **57**: 1553-1559 [PMID: 19018029 DOI: 10.1099/jmm.0.2008/003715-0]
  - 178 **Yildirim B**, Öztürk MA, Unal S. The anti-*Helicobacter pylori* antibiotherapy for the treatment of recurrent oral aphthous ulcers in a patient with Behçet's syndrome. *Rheumatol Int* 2009; **29**: 477-478 [PMID: 18802701 DOI: 10.1007/s00296-008-0709-2]
  - 179 **Attia EA**, Abdel Fattah NS, Abdella HM. Upper gastrointestinal findings and detection of *Helicobacter pylori* in patients with oral lichen planus. *Clin Exp Dermatol* 2010; **35**: 355-360 [PMID: 19663844 DOI: 10.1111/j.1365-2230.2009.03464.x]
  - 180 **Pourshahidi S**, Fakhri F, Ebrahimi H, Fakhraei B, Alipour A, Ghapanchi J, Farjadian S. Lack of association between *Helicobacter pylori* infection and oral lichen planus. *Asian Pac J Cancer Prev* 2012; **13**: 1745-1747 [PMID: 22901114]
  - 181 **Cecchini MP**, Pellegrini C, Bassetto MA, Osculati F, Sbarbati A, Marcolini L, Pegoraro M, Fontana R, De Franceschi L. Might *Helicobacter pylori* infection be associated with distortion on taste perception? *Med Hypotheses* 2013; **81**: 496-499 [PMID: 23845559 DOI: 10.1016/j.mehy.2013.06.018]
  - 182 **Zaric S**, Bojic B, Jankovic Lj, Dapcevic B, Popovic B, Cakic S, Milasin J. Periodontal therapy improves gastric *Helicobacter pylori* eradication. *J Dent Res* 2009; **88**: 946-950 [PMID: 19783805 DOI: 10.1177/0022034509344559]
  - 183 **Namiot DB**, Leszczyńska K, Namiot Z, Chlewicki M, Bucki R, Kemonia A. The occurrence of *Helicobacter pylori* antigens in dental plaque; an association with oral health status and oral hygiene practices. *Adv Med Sci* 2010; **55**: 167-171 [PMID: 20934966 DOI: 10.2478/v10039-010-0032-5]
  - 184 **Chaudhry S**, Khan AA, Butt AK, Idrees M, Izhar M, Iqbal HA. *Helicobacter pylori* in dental plaque; is it related to brushing frequency, plaque load and oral health status? *J Coll Physicians Surg Pak* 2011; **21**: 589-592 [PMID: 22015117 DOI: 10.2011/JCPSP.589592]
  - 185 **Mravak-Stipetić M**, Gall-Troselj K, Lukac J, Kusić Z, Pavelić K, Pavelić J. Detection of *Helicobacter pylori* in various oral lesions by nested polymerase chain reaction (PCR). *J Oral Pathol Med* 1998; **27**: 1-3 [PMID: 9466726]
  - 186 **Loster BW**, Czesnikiewicz-Guzik M, Bielanski W, Karczewska E, Loster JE, Kalukin J, Guzik TJ, Majewski S, Konturek SJ. Prevalence and characterization of *Helicobacter pylori* (H. pylori) infection and colonization in dentists. *J Physiol Pharmacol* 2009; **60** Suppl 8: 13-18 [PMID: 20400786]
  - 187 **Nguyen AM**, el-Zaatari FA, Graham DY. *Helicobacter pylori* in the oral cavity. A critical review of the literature. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1995; **79**: 705-709 [PMID: 7621027]
  - 188 **Najafipour R**, Farivar TN, Pahlevan AA, Johari P, Safdarian F, Asefzadeh M. Agreement rate of rapid urease test, conventional PCR, and scorpion real-time PCR in detecting

- helicobacter pylori from tonsillar samples of patients with chronic tonsillitis. *J Glob Infect Dis* 2012; **4**: 106-109 [PMID: 22754245 DOI: 10.4103/0974-777X.96773]
- 189 **Farivar TN**, Pahlevan A, Johari P, Safdarian F, Mehr MA, Najafipour R, Ahmadpour F. Assessment of helicobacter pylori prevalence by scorpion real-time PCR in chronic tonsillitis patients. *J Glob Infect Dis* 2012; **4**: 38-42 [PMID: 22529626 DOI: 10.4103/0974-777X.93760]
  - 190 **Uygur-Bayramiçli O**, Yavuzer D, Dabak R, Aydın S, Kurt N. Helicobacter pylori colonization on tonsil tissue. *Am J Gastroenterol* 2002; **97**: 2470-2471 [PMID: 12358279]
  - 191 **Jabbari Moghaddam Y**, Rafeey M, Radfar R. Comparative assessment of Helicobacter pylori colonization in children tonsillar tissues. *Int J Pediatr Otorhinolaryngol* 2009; **73**: 1199-1201 [PMID: 19523691 DOI: 10.1016/j.ijporl.2009.05.005]
  - 192 **Wibawa T**, Surono A, Widodo I. Isolation of viable Helicobacter pylori in the tonsillar tissues of chronic tonsillitis patients. *J Infect Dev Ctries* 2011; **5**: 561-564 [PMID: 21795828]
  - 193 **Nártová E**, Kraus J, Pavlík E, Lukeš P, Katra R, Plzák J, Kolářová L, Sterzl I, Betka J, Astl J. Presence of different genotypes of Helicobacter pylori in patients with chronic tonsillitis and sleep apnoea syndrome. *Eur Arch Otorhinolaryngol* 2013; Epub ahead of print [PMID: 23864246 DOI: 10.1007/s00405-013-2607-9]
  - 194 **Khademi B**, Niknejad N, Gandomi B, Yeganeh F. Comparison of Helicobacter pylori colonization on the tonsillar surface versus tonsillar core tissue as determined by the CLO test. *Ear Nose Throat J* 2007; **86**: 498-501 [PMID: 17915674]
  - 195 **Aslan S**, Yılmaz I, Bal N, Sener M, Butros R, Demirhan B, Ozluoglu LN. Investigation of Helicobacter pylori in tonsillary tissue with Pronto Dry test and pathologic examination. *Auris Nasus Larynx* 2007; **34**: 339-342 [PMID: 17196780]
  - 196 **Fazaeli A**. State of the globe: Diagnostic tests to detect Helicobacter pylori tonsillitis. *J Glob Infect Dis* 2012; **4**: 99-101 [PMID: 22754243 DOI: 10.4103/0974-777X.96765]
  - 197 **Lin HC**, Wu PY, Friedman M, Chang HW, Wilson M. Difference of Helicobacter pylori colonization in recurrent inflammatory and simple hyperplastic tonsil tissues. *Arch Otolaryngol Head Neck Surg* 2010; **136**: 468-470 [PMID: 20479377 DOI: 10.1001/archoto.2010.63]
  - 198 **Minocha A**, Raczkowski CA, Richards RJ. Is a history of tonsillectomy associated with a decreased risk of Helicobacter pylori infection? *J Clin Gastroenterol* 1997; **25**: 580-582 [PMID: 9451666]
  - 199 **Sezen OS**, Kubilay U, Erzin Y, Tuncer M, Unver S. Does tonsillectomy affect the outcome of drug treatment for the eradication of gastric H pylori infection? A pilot study. *Ear Nose Throat J* 2013; **92**: 127-132 [PMID: 23532649]
  - 200 **Lukeš P**, Pavlík E, Potužníková B, Plzák J, Nártová E, Doseděl J, Katra R, Sterzl I, Betka J, Astl J. Comparison of Helicobacter pylori genotypes obtained from the oropharynx and stomach of the same individuals - a pilot study. *Prague Med Rep* 2012; **113**: 231-239 [PMID: 22980564]
  - 201 **Kusano K**, Tokunaga O, Ando T, Inokuchi A. Helicobacter pylori in the palatine tonsils of patients with IgA nephropathy compared with those of patients with recurrent pharyngotonsillitis. *Hum Pathol* 2007; **38**: 1788-1797 [PMID: 17714758]
  - 202 **Kusano K**, Inokuchi A, Fujimoto K, Miyamoto H, Tokunaga O, Kuratomi Y, Shimazu R, Mori D, Yamasaki F, Kidera K, Tsunetomi K, Miyazaki J. Coccoid Helicobacter pylori exists in the palatine tonsils of patients with IgA nephropathy. *J Gastroenterol* 2010; **45**: 406-412 [PMID: 19997853 DOI: 10.1007/s00535-009-0169-9]
  - 203 **Yılmaz M**, Kara CO, Kaleli I, Demir M, Tümkaya F, Büke AS, Topuz B. Are tonsils a reservoir for Helicobacter pylori infection in children? *Int J Pediatr Otorhinolaryngol* 2004; **68**: 307-310 [PMID: 15129940]
  - 204 **Skinner LJ**, Winter DC, Curran AJ, Barnes C, Kennedy S, Maguire AJ, Charles DA, Timon CI, Burns HP. Helicobacter pylori and tonsillectomy. *Clin Otolaryngol Allied Sci* 2001; **26**: 505-509 [PMID: 11843933]
  - 205 **Jelavic B**, Bevanda M, Ostojic M, Leventic M, Vasilj M, Knezevic E. Tonsillar colonization is unlikely to play important role in Helicobacter pylori infection in children. *Int J Pediatr Otorhinolaryngol* 2007; **71**: 585-590 [PMID: 17239446]
  - 206 **Di Bonaventura G**, Catamo G, Neri M, Neri G, Piccolomini R. Absence of Helicobacter pylori in tonsillar swabs from dyspeptic patients. *New Microbiol* 2000; **23**: 445-448 [PMID: 11061634]
  - 207 **di Bonaventura G**, Neri M, Neri G, Catamo G, Piccolomini R. Do tonsils represent an extragastric reservoir for Helicobacter pylori infection. *J Infect* 2001; **42**: 221-222 [PMID: 11545561]
  - 208 **Aladag I**, Bulut Y, Guven M, Eyibilen A, Yelken K. Seroprevalence of Helicobacter pylori infection in patients with chronic nonspecific pharyngitis: preliminary study. *J Laryngol Otol* 2008; **122**: 61-64 [PMID: 17352845]
  - 209 **Tauber S**, Gross M, Issing WJ. Association of laryngopharyngeal symptoms with gastroesophageal reflux disease. *Laryngoscope* 2002; **112**: 879-886 [PMID: 12150622]
  - 210 **Yazici ZM**, Sayin I, Kayhan FT, Biskin S. Laryngopharyngeal reflux might play a role on chronic nonspecific pharyngitis. *Eur Arch Otorhinolaryngol* 2010; **267**: 571-574 [PMID: 19629512 DOI: 10.1007/s00405-009-1044-2]
  - 211 **Zhang JP**, Peng ZH, Zhang J, Zhang XH, Zheng QY. Helicobacter pylori infection in the pharynx of patients with chronic pharyngitis detected with TDI-FP and modified Giemsa stain. *World J Gastroenterol* 2006; **12**: 468-472 [PMID: 16489652]
  - 212 **Kaplan ZK**, Emir H, Uzunkulaoglu H, Yücel M, Karakoç E, Koca G, Tüzüner A, Samim E, Korkmaz M. Determination of Helicobacter pylori in patients with chronic nonspecific pharyngitis. *Laryngoscope* 2009; **119**: 1479-1483 [PMID: 19504600 DOI: 10.1002/lary.20253]
  - 213 **Elsheikh MN**, Mahfouz ME. Prevalence of Helicobacter pylori DNA in recurrent aphthous ulcerations in mucosa-associated lymphoid tissues of the pharynx. *Arch Otolaryngol Head Neck Surg* 2005; **131**: 804-808 [PMID: 16172360]
  - 214 **Shaker R**, Milbrath M, Ren J, Toohill R, Hogan WJ, Li Q, Hofmann CL. Esophagopharyngeal distribution of refluxed gastric acid in patients with reflux laryngitis. *Gastroenterology* 1995; **109**: 1575-1582 [PMID: 7557141]
  - 215 **Cekin E**, Ozyurt M, Erkul E, Ergunay K, Cincik H, Kapucu B, Gungor A. The association between Helicobacter pylori and laryngopharyngeal reflux in laryngeal pathologies. *Ear Nose Throat J* 2012; **91**: E6-E9 [PMID: 22430349]
  - 216 **Rouev P**, Chakarski I, Doskov D, Dimov G, Staykova E. Laryngopharyngeal symptoms and gastroesophageal reflux disease. *J Voice* 2005; **19**: 476-480 [PMID: 15936924]
  - 217 **Youssef TF**, Ahmed MR. Treatment of clinically diagnosed laryngopharyngeal reflux disease. *Arch Otolaryngol Head Neck Surg* 2010; **136**: 1089-1092 [PMID: 20855671 DOI: 10.1001/archoto.2010.165]
  - 218 **Wong RK**, Hanson DG, Waring PJ, Shaw G. ENT manifestations of gastroesophageal reflux. *Am J Gastroenterol* 2000; **95**: S15-S22 [PMID: 10950101]
  - 219 **Toros SZ**, Toros AB, Yüksel OD, Ozel L, Akkaynak C, Naiboglu B. Association of laryngopharyngeal manifestations and gastroesophageal reflux. *Eur Arch Otorhinolaryngol* 2009; **266**: 403-409 [PMID: 18648836 DOI: 10.1007/s00405-008-0761-2]
  - 220 **Koufman JA**, Amin MR, Panetti M. Prevalence of reflux in 113 consecutive patients with laryngeal and voice disorders. *Otolaryngol Head Neck Surg* 2000; **123**: 385-388 [PMID: 11020172]
  - 221 **Koufman JA**. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. *Laryngoscope* 1991;



- 101: 1-78 [PMID: 1895864]
- 222 **Rubin JS**, Benjamin E, Prior A, Lavy J, Ratcliffe P. The prevalence of *Helicobacter pylori* infection in benign laryngeal disorders. *J Voice* 2002; **16**: 87-91 [PMID: 12002892]
- 223 **Talaat M**, Gad MS, Magdy EA, Aggag SM, Nour YA. *Helicobacter pylori* infection and chronic, persistent cough: is there an association? *J Laryngol Otol* 2007; **121**: 962-967 [PMID: 17295933]
- 224 **Tiba M**, Fawaz S, Osman H. *Helicobacter pylori* and its role in vocal folds' minimal lesions. *Clin Respir J* 2010; **4**: 237-240 [PMID: 20887347 DOI: 10.1111/j.1752-699X.2009.00182.x]
- 225 **Dworkin JP**. Laryngitis: types, causes, and treatments. *Otolaryngol Clin North Am* 2008; **41**: 419-436, ix [PMID: 18328379 DOI: 10.1016/j.otc.2007.11.011]
- 226 **Borkowski G**, Sudhoff H, Koslowski F, Hackstedt G, Radü HJ, Luckhaupt H. A possible role of *Helicobacter pylori* infection in the etiology of chronic laryngitis. *Eur Arch Otorhinolaryngol* 1997; **254**: 481-482 [PMID: 9438124 DOI: 10.1007/BF02439987]
- 227 **Siupsinskiene N**, Jurgutaviciute V, Katutiene I, Janciauskas D, Vaitkus S, Adamonis K. *Helicobacter pylori* infection in laryngeal diseases. *Eur Arch Otorhinolaryngol* 2013; **270**: 2283-2288 [PMID: 23572292 DOI: 10.1007/s00405-013-2475-3]
- 228 **Jaspersen D**, Weber R, Diehl KL, Kind M, Arps H, Draf W. Is chronic laryngitis associated with *Helicobacter pylori*? Results of a prospective study. *Z Gastroenterol* 1998; **36**: 369-372 [PMID: 9654703]
- 229 **Deng B**, Li Y, Zhang Y, Bai L, Yang P. *Helicobacter pylori* infection and lung cancer: a review of an emerging hypothesis. *Carcinogenesis* 2013; **34**: 1189-1195 [PMID: 23568955 DOI: 10.1093/carcin/bgt114]
- 230 **Shi Y**, Gong H, Zhou L, Tao L, Shi Y, Cao W, Cheng L. Association between *Helicobacter pylori* infection and laryngeal squamous cell carcinoma in a Chinese male population. *ORL J Otorhinolaryngol Relat Spec* 2011; **73**: 295-300 [PMID: 21952073 DOI: 10.1159/000330955]
- 231 **Aygenç E**, Selcuk A, Celikkanat S, Ozbek C, Ozdem C. The role of *Helicobacter pylori* infection in the cause of squamous cell carcinoma of the larynx. *Otolaryngol Head Neck Surg* 2001; **125**: 520-521 [PMID: 11700453]
- 232 **Okuda K**, Ishihara K, Miura T, Katakura A, Noma H, Ebihara Y. *Helicobacter pylori* may have only a transient presence in the oral cavity and on the surface of oral cancer. *Microbiol Immunol* 2000; **44**: 385-388 [PMID: 10888357]
- 233 **Burduk PK**. The role of *Helicobacter pylori* infection in carcinoma of the larynx. *Otolaryngol Pol* 2006; **60**: 521-523 [PMID: 17152803]
- 234 **Dayama A**, Srivastava V, Shukla M, Singh R, Pandey M. *Helicobacter pylori* and oral cancer: possible association in a preliminary case control study. *Asian Pac J Cancer Prev* 2011; **12**: 1333-1336 [PMID: 21875292]
- 235 **Rubin JS**, Benjamin E, Prior A, Lavy J. The prevalence of *Helicobacter pylori* infection in malignant and premalignant conditions of the head and neck. *J Laryngol Otol* 2003; **117**: 118-121 [PMID: 12625884]
- 236 **Rezaii J**, Tavakoli H, Esfandiari K, Ashegh H, Hasibi M, Ghanei G, Khosh-Batn M, Rashidi A. Association between *Helicobacter pylori* infection and laryngo-hypopharyngeal carcinoma: a case-control study and review of the literature. *Head Neck* 2008; **30**: 1624-1627 [PMID: 18767170 DOI: 10.1002/hed.20918]
- 237 **Gong H**, Shi Y, Zhou L, Tao L, Shi Y, Cao W, Cheng L. *Helicobacter pylori* infection of the larynx may be an emerging risk factor for laryngeal squamous cell carcinoma. *Clin Transl Oncol* 2012; **14**: 905-910 [PMID: 22855167 DOI: 10.1007/s12094-012-0879-y]
- 238 **Grimm M**, Munz A, Exarchou A, Poligkeit J, Reinert S. Immunohistochemical detection of *Helicobacter pylori* without association of TLR5 expression in oral squamous cell carcinoma. *J Oral Pathol Med* 2014; **43**: 35-44 [PMID: 23659788 DOI: 10.1111/jop.12082]
- 239 **Singh K**, Kumar S, Jaiswal MS, Chandra M, Singh M. Absence of *Helicobacter pylori* in oral mucosal lesions. *J Indian Med Assoc* 1998; **96**: 177-178 [PMID: 9834566]
- 240 **Satheeshkumar PS**, Mohan MP. Oral *Helicobacter pylori* infection and the risk of oral cancer. *Oral Oncol* 2013; **49**: e20-e21 [PMID: 23481311 DOI: 10.1016/j.oraloncology.2013.02.007]
- 241 **Kizilay A**, Saydam L, Aydin A, Kalciglu MT, Ozturan O, Aydin NE. Histopathologic examination for *Helicobacter pylori* as a possible etiopathogenic factor in laryngeal carcinoma. *Chemotherapy* 2006; **52**: 80-82 [PMID: 16498240]
- 242 **Akbayir N**, Başak T, Seven H, Sungun A, Erdem L. Investigation of *Helicobacter pylori* colonization in laryngeal neoplasia. *Eur Arch Otorhinolaryngol* 2005; **262**: 170-172 [PMID: 15821906 DOI: 10.1007/s00405-004-0794-0]
- 243 **Pirzadeh A**, Doustmohammadian N, Khoshbaten M, Doustmohammadian S. Is there any association between *Helicobacter Pylori* infection and laryngeal carcinoma? *Asian Pac J Cancer Prev* 2011; **12**: 897-900 [PMID: 21790222]
- 244 **Kanda T**, Tanaka S, Asato R, Tamaki H, Ito J, Morinaka S. Investigation of *Helicobacter Pylori* in tumor tissue specimens from patients of head and neck tumor. *Practica Oto-Rhino-Laryngologica* 2005; **98**: 571-575
- 245 **Grandis JR**, Perez-Perez GI, Yu VL, Johnson JT, Blaser MJ. Lack of serologic evidence for *Helicobacter pylori* infection in head and neck cancer. *Head Neck* 1997; **19**: 216-218 [PMID: 9142522 DOI: 10.1002/(SICI)1097-0347(199705)19:3<216::AID-HED9>3.0.CO;2-5]
- 246 **Nurgalieva ZZ**, Graham DY, Dahlstrom KR, Wei Q, Sturgis EM. A pilot study of *Helicobacter pylori* infection and risk of laryngopharyngeal cancer. *Head Neck* 2005; **27**: 22-27 [PMID: 15459921 DOI: 10.1002/hed.20108]
- 247 **Lukes P**, Astl J, Pavlík E, Potuzníková B, Sterzl I, Betka J. *Helicobacter pylori* in tonsillar and adenoid tissue and its possible role in oropharyngeal carcinogenesis. *Folia Biol (Praha)* 2008; **54**: 33-39 [PMID: 18498719]
- 248 **Lukeš P**, Pavlík E, Potuznikova B, Nartova E, Foltynova E, Plzak J, Katra R, Sterzl I, Bartunkova J, Betka J, Astl J. Detection of *Helicobacter pylori* in oropharyngeal lymphatic tissue with real-time PCR and assessment of its carcinogenic potential. *Eur Arch Otorhinolaryngol* 2013; Epub ahead of print [PMID: 23744180 DOI: 10.1007/s00405-013-2574-1]
- 249 **Pavlík E**, Lukes P, Potuzníková B, Astl J, Hrdá P, Soucek A, Matucha P, Doseděl J, Sterzl I. *Helicobacter pylori* isolated from patients with tonsillar cancer or tonsillitis chronica could be of different genotype compared to isolates from gastrointestinal tract. *Folia Microbiol (Praha)* 2007; **52**: 91-94 [PMID: 17571803]
- 250 **Sugimoto M**, Zali MR, Yamaoka Y. The association of vacA genotypes and *Helicobacter pylori*-related gastroduodenal diseases in the Middle East. *Eur J Clin Microbiol Infect Dis* 2009; **28**: 1227-1236 [PMID: 19551413 DOI: 10.1007/s10096-009-0772-y]
- 251 **Malaty HM**. Epidemiology of *Helicobacter pylori* infection. *Best Pract Res Clin Gastroenterol* 2007; **21**: 205-214 [PMID: 17382273]

P- Reviewers: Lee YY, Ozturk Y S- Editor: Zhai HH

L- Editor: A E- Editor: Wang CH





Published by **Baishideng Publishing Group Co., Limited**

Flat C, 23/F., Lucky Plaza,  
315-321 Lockhart Road, Wan Chai, Hong Kong, China

Fax: +852-65557188

Telephone: +852-31779906

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>



ISSN 1007-9327

